Healthcare Trust of America (HTA) 10-Q 25 Oct 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 23, 2017
Entity Information [Line Items]
Entity Registrant Name	HEALTHCARE TRUST OF AMERICA, INC.
Entity Central Index Key	1,360,604
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		204,886,019
Healthcare Trust of America Holdings, LP (HTALP)
Entity Information [Line Items]
Entity Registrant Name	Healthcare Trust of America Holdings, LP
Entity Central Index Key	1,495,491
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Real estate investments:
Land	$ 480,850	$ 386,526
Building and improvements	5,788,837	3,466,516
Lease intangibles	648,591	467,571
Construction in progress	59,573	0
Real estate investments, gross	6,977,851	4,320,613
Accumulated depreciation and amortization	(973,566)	(817,593)
Real estate investments, net	6,004,285	3,503,020
Investment in unconsolidated joint venture	68,303	0
Cash and cash equivalents	9,410	11,231
Restricted cash and escrow deposits	17,469	13,814
Receivables and other assets, net	206,030	173,461
Other intangibles, net	108,025	46,318
Total assets	6,413,522	3,747,844
Liabilities:
Debt	2,856,758	1,768,905
Accounts payable and accrued liabilities	159,070	105,034
Derivative financial instruments - interest rate swaps	1,441	1,920
Security deposits, prepaid rent and other liabilities	61,402	49,859
Intangible liabilities, net	69,852	37,056
Total liabilities	3,148,523	1,962,774
Commitments and contingencies
Redeemable noncontrolling interests	4,692	4,653
Equity/Partners' Capital:
Preferred stock, $0.01 par value; 200,000,000 shares authorized; none issued and outstanding	0	0
Class A common stock, $0.01 par value; 1,000,000,000 shares authorized; 200,686,673 and 141,719,134 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively	2,007	1,417
Additional paid-in capital	4,386,224	2,754,818
Accumulated other comprehensive loss	(615)	0
Cumulative dividends in excess of earnings	(1,212,051)	(1,068,961)
Total stockholders’ equity	3,175,565	1,687,274
Noncontrolling interests	84,742	93,143
Total equity	3,260,307	1,780,417
Total liabilities and equity/partners' capital	6,413,522	3,747,844
Healthcare Trust of America Holdings, LP (HTALP)
Real estate investments:
Land	480,850	386,526
Building and improvements	5,788,837	3,466,516
Lease intangibles	648,591	467,571
Construction in progress	59,573	0
Real estate investments, gross	6,977,851	4,320,613
Accumulated depreciation and amortization	(973,566)	(817,593)
Real estate investments, net	6,004,285	3,503,020
Investment in unconsolidated joint venture	68,303	0
Cash and cash equivalents	9,410	11,231
Restricted cash and escrow deposits	17,469	13,814
Receivables and other assets, net	206,030	173,461
Other intangibles, net	108,025	46,318
Total assets	6,413,522	3,747,844
Liabilities:
Debt	2,856,758	1,768,905
Accounts payable and accrued liabilities	159,070	105,034
Derivative financial instruments - interest rate swaps	1,441	1,920
Security deposits, prepaid rent and other liabilities	61,402	49,859
Intangible liabilities, net	69,852	37,056
Total liabilities	3,148,523	1,962,774
Commitments and contingencies
Redeemable noncontrolling interests	4,692	4,653
Equity/Partners' Capital:
Limited partners’ capital, 4,116,546 and 4,323,095 units issued and outstanding as of September 30, 2017 and December 31, 2016, respectively	84,472	92,873
General partners’ capital, 200,686,673 and 141,719,134 units issued and outstanding as of September 30, 2017 and December 31, 2016, respectively	3,175,835	1,687,544
Total partners’ capital	3,260,307	1,780,417
Total liabilities and equity/partners' capital	$ 6,413,522	$ 3,747,844

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	200,000,000	200,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Healthcare Trust of America Holdings, LP (HTALP)
Partners’ Capital:
Limited partner's capital, units issued (in shares)	4,116,546	4,323,095
Limited partner's capital, units outstanding (in shares)	4,116,546	4,323,095
General partner's capital, units issued (in shares)	200,686,673	141,719,134
General partner's capital, units outstanding (in shares)	200,686,673	141,719,134
Class A Common Stock
Equity:
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	200,686,673	141,719,134
Common stock, shares outstanding (in shares)	200,686,673	141,719,134

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues:
Rental income		$ 175,431,000	$ 118,252,000	$ 438,949,000	$ 338,646,000
Interest and other operating income		563,000	88,000	1,271,000	243,000
Total revenues		175,994,000	118,340,000	440,220,000	338,889,000
Expenses:
Rental		56,331,000	36,885,000	138,874,000	105,299,000
General and administrative		8,283,000	7,293,000	25,178,000	20,879,000
Transaction		261,000	1,122,000	5,618,000	4,997,000
Depreciation and amortization		70,491,000	47,864,000	172,900,000	130,430,000
Impairment		0	0	5,093,000	0
Total expenses		135,366,000	93,164,000	347,663,000	261,605,000
Income before other income (expense)		40,628,000	25,176,000	92,557,000	77,284,000
Interest expense:
Interest related to derivative financial instruments		(264,000)	(552,000)	(827,000)	(1,856,000)
Gain (loss) on change in fair value of derivative financial instruments, net		0	1,306,000	884,000	(2,144,000)
Total interest related to derivative financial instruments, including net change in fair value of derivative financial instruments		(264,000)	754,000	57,000	(4,000,000)
Interest related to debt		(25,924,000)	(16,386,000)	(59,688,000)	(44,503,000)
Gain on sale of real estate, net		0	0	3,000	4,212,000
Loss on extinguishment of debt, net		(774,000)	(3,000,000)	(11,192,000)	(3,022,000)
Income from unconsolidated joint venture		318,000	0	381,000	0
Other (expense) income		(27,000)	95,000	(13,000)	220,000
Net income		13,957,000	6,639,000	22,105,000	30,191,000
Net income attributable to noncontrolling interests	[1]	(194,000)	(212,000)	(715,000)	(830,000)
Net (loss) income attributable to common stockholders/unitholders		$ 13,763,000	$ 6,427,000	$ 21,390,000	$ 29,361,000
Earnings per common share/unit - basic:
Net income attributable to common stockholders/unitholders (in dollars per share)		$ 0.07	$ 0.05	$ 0.12	$ 0.22
Earnings per common share/unit - diluted:
Net income attributable to common stockholders/unitholders (in dollars per share)		$ 0.07	$ 0.04	$ 0.12	$ 0.21
Weighted average common shares/units outstanding:
Basic (in shares)		200,674	138,807	173,189	134,905
Diluted (in shares)		204,795	143,138	177,410	138,314
Dividends declared per common share/common unit (in dollars per share)		$ 0.305	$ 0.300	$ 0.905	$ 0.890
Healthcare Trust of America Holdings, LP (HTALP)
Revenues:
Rental income		$ 175,431,000	$ 118,252,000	$ 438,949,000	$ 338,646,000
Interest and other operating income		563,000	88,000	1,271,000	243,000
Total revenues		175,994,000	118,340,000	440,220,000	338,889,000
Expenses:
Rental		56,331,000	36,885,000	138,874,000	105,299,000
General and administrative		8,283,000	7,293,000	25,178,000	20,879,000
Transaction		261,000	1,122,000	5,618,000	4,997,000
Depreciation and amortization		70,491,000	47,864,000	172,900,000	130,430,000
Impairment		0	0	5,093,000	0
Total expenses		135,366,000	93,164,000	347,663,000	261,605,000
Income before other income (expense)		40,628,000	25,176,000	92,557,000	77,284,000
Interest expense:
Interest related to derivative financial instruments		(264,000)	(552,000)	(827,000)	(1,856,000)
Gain (loss) on change in fair value of derivative financial instruments, net		0	1,306,000	884,000	(2,144,000)
Total interest related to derivative financial instruments, including net change in fair value of derivative financial instruments		(264,000)	754,000	57,000	(4,000,000)
Interest related to debt		(25,924,000)	(16,386,000)	(59,688,000)	(44,503,000)
Gain on sale of real estate, net		0	0	3,000	4,212,000
Loss on extinguishment of debt, net		(774,000)	(3,000,000)	(11,192,000)	(3,022,000)
Income from unconsolidated joint venture		318,000	0	381,000	0
Other (expense) income		(27,000)	95,000	(13,000)	220,000
Net income		13,957,000	6,639,000	22,105,000	30,191,000
Net income attributable to noncontrolling interests		(28,000)	(1,000)	(80,000)	(28,000)
Net (loss) income attributable to common stockholders/unitholders		$ 13,929,000	$ 6,638,000	$ 22,025,000	$ 30,163,000
Earnings per common share/unit - basic:
Net income attributable to common stockholders/unitholders (in dollars per share)		$ 0.07	$ 0.05	$ 0.12	$ 0.22
Earnings per common share/unit - diluted:
Net income attributable to common stockholders/unitholders (in dollars per share)		$ 0.07	$ 0.05	$ 0.12	$ 0.22
Weighted average common shares/units outstanding:
Basic (in shares)		204,795	143,137	177,410	138,314
Diluted (in shares)		204,795	143,137	177,410	138,314
Dividends declared per common share/common unit (in dollars per share)		$ 0.305	$ 0.300	$ 0.905	$ 0.890
[1]	Includes amounts attributable to redeemable noncontrolling interests.

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Net income	$ 13,957	$ 6,639	$ 22,105	$ 30,191
Other comprehensive gain (loss)
Change in unrealized gains (losses) on cash flow hedges	205	0	(631)	0
Total other comprehensive gain (loss)	205	0	(631)	0
Total comprehensive income	14,162	6,639	21,474	30,191
Comprehensive income attributable to noncontrolling interests	(170)	(211)	(619)	(802)
Total comprehensive income attributable to common stockholders/unitholders	13,992	6,428	20,855	29,389
Healthcare Trust of America Holdings, LP (HTALP)
Net income	13,957	6,639	22,105	30,191
Other comprehensive gain (loss)
Change in unrealized gains (losses) on cash flow hedges	205	0	(631)	0
Total other comprehensive gain (loss)	205	0	(631)	0
Total comprehensive income	14,162	6,639	21,474	30,191
Comprehensive income attributable to noncontrolling interests	(28)	(1)	(80)	(28)
Total comprehensive income attributable to common stockholders/unitholders	$ 14,134	$ 6,638	$ 21,394	$ 30,163

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - USD ($) $ in Thousands	Total	Class A Common Stock	Common StockClass A Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Cumulative Dividends in Excess of Earnings	Total Stockholders’ Equity	Noncontrolling Interests
Beginning balance at Dec. 31, 2015	$ 1,406,958		$ 1,270	$ 2,328,806	$ 0	$ (950,652)	$ 1,379,424	$ 27,534
Beginning balance (in shares) at Dec. 31, 2015			127,027,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net	417,163		$ 141	417,022			417,163
Issuance of common stock, net (in shares)			14,138,000
Issuance of operating partnership units in connection with an acquisition	71,754							71,754
Share-based award transactions, net	5,136		$ 4	5,132			5,136
Share-based award transactions, net (in shares)			393,000
Repurchase and cancellation of common stock	(2,425)		$ (1)	(2,424)			(2,425)
Repurchase and cancellation of common stock (in shares)			(87,000)
Redemption of noncontrolling interest and other	(676)		$ 3	5,030			5,033	(5,709)
Redemption of noncontrolling interest and other (in shares)			257,000
Dividends declared	(124,820)					(121,686)	(121,686)	(3,134)
Net income	30,163					29,361	29,361	802
Other comprehensive loss	0
Ending balance at Sep. 30, 2016	1,803,253		$ 1,417	2,753,566	0	(1,042,977)	1,712,006	91,247
Ending balance (in shares) at Sep. 30, 2016			141,728,000
Beginning balance at Dec. 31, 2016	1,780,417		$ 1,417	2,754,818	0	(1,068,961)	1,687,274	93,143
Beginning balance (in shares) at Dec. 31, 2016		141,719,134	141,719,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net	1,624,222		$ 586	1,623,636			1,624,222
Issuance of common stock, net (in shares)			58,623,000
Issuance of operating partnership units in connection with an acquisition	610							610
Share-based award transactions, net	5,493		$ 3	5,490			5,493
Share-based award transactions, net (in shares)			234,000
Repurchase and cancellation of common stock	(3,413)		$ (1)	(3,412)			(3,413)
Repurchase and cancellation of common stock (in shares)			(116,000)
Redemption of noncontrolling interest and other	0		$ 2	5,692			5,694	(5,694)
Redemption of noncontrolling interest and other (in shares)			227,000
Dividends declared	(168,416)					(164,480)	(164,480)	(3,936)
Net income	22,025					21,390	21,390	635
Other comprehensive loss	(631)				(615)		(615)	(16)
Ending balance at Sep. 30, 2017	$ 3,260,307		$ 2,007	$ 4,386,224	$ (615)	$ (1,212,051)	$ 3,175,565	$ 84,742
Ending balance (in shares) at Sep. 30, 2017		200,686,673	200,687,000

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN PARTNERS' CAPITAL - USD ($) $ in Thousands	Total	Healthcare Trust of America Holdings, LP (HTALP)	Healthcare Trust of America Holdings, LP (HTALP)General Partners’ Capital	Healthcare Trust of America Holdings, LP (HTALP)Limited Partners’ Capital
Balance as of beginning of period at Dec. 31, 2015		$ 1,406,958	$ 1,379,694	$ 27,264
Balance as of beginning of period (in units) at Dec. 31, 2015			127,027,000	1,930,000
Increase (Decrease) in Partners' Capital [Roll Forward]
Issuance of general partner units, net		417,163	$ 417,163
Issuance of general partner units, net (in units)			14,138,000
Issuance of limited partner units in connection with an acquisition		71,754		$ 71,754
Issuance of limited partner units in connection with an acquisition (in units)				2,650,000
Share-based award transactions, net		5,136	$ 5,136
Share-based award transactions, net (in units)			393,000
Redemption and cancellation of general partner units		(2,425)	$ (2,425)
Redemption and cancellation of general partner units (in units)			(87,000)
Redemption of limited partner units and other		(676)	$ 5,033	$ (5,709)
Redemption of limited partner units and other (in units)			257,000	(257,000)
Distributions declared		(124,820)	$ (121,686)	$ (3,134)
Net income	$ 29,361	30,163	29,361	802
Other comprehensive loss	0	0
Balance as of end of period at Sep. 30, 2016		1,803,253	$ 1,712,276	$ 90,977
Balance as of end of period (in units) at Sep. 30, 2016			141,728,000	4,323,000
Balance as of beginning of period at Dec. 31, 2016		1,780,417	$ 1,687,544	$ 92,873
Balance as of beginning of period (in units) at Dec. 31, 2016			141,719,000	4,323,000
Increase (Decrease) in Partners' Capital [Roll Forward]
Issuance of general partner units, net		1,624,222	$ 1,624,222
Issuance of general partner units, net (in units)			58,623,000
Issuance of limited partner units in connection with an acquisition		$ 610		$ 610
Issuance of limited partner units in connection with an acquisition (in units)		20,687		21,000
Share-based award transactions, net		$ 5,493	$ 5,493
Share-based award transactions, net (in units)			234,000
Redemption and cancellation of general partner units		(3,413)	$ (3,413)
Redemption and cancellation of general partner units (in units)			(116,000)
Redemption of limited partner units and other		0	$ 5,694	$ (5,694)
Redemption of limited partner units and other (in units)			227,000	(227,000)
Distributions declared		(168,416)	$ (164,480)	$ (3,936)
Net income	21,390	22,025	21,390	635
Other comprehensive loss	$ (631)	(631)	(615)	(16)
Balance as of end of period at Sep. 30, 2017		$ 3,260,307	$ 3,175,835	$ 84,472
Balance as of end of period (in units) at Sep. 30, 2017			200,687,000	4,117,000

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net income	$ 22,105,000	$ 30,191,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization and other	169,057,000	128,728,000
Share-based compensation expense	5,493,000	5,136,000
Bad debt expense	635,000	508,000
Impairment	5,093,000	0
Income from unconsolidated joint venture	(381,000)	0
Gain on sale of real estate, net	(3,000)	(4,212,000)
Loss on extinguishment of debt, net	11,192,000	3,022,000
Change in fair value of derivative financial instruments	(884,000)	2,144,000
Changes in operating assets and liabilities:
Receivables and other assets, net	(20,489,000)	(14,051,000)
Accounts payable and accrued liabilities	29,566,000	3,598,000
Prepaid rent and other liabilities	7,158,000	(6,807,000)
Net cash provided by operating activities	228,542,000	148,257,000
Cash flows from investing activities:
Investments in real estate	(2,357,570,000)	(532,527,000)
Investment in unconsolidated joint venture	(68,839,000)	0
Development of real estate	(19,163,000)	0
Proceeds from the sale of real estate	4,746,000	23,368,000
Capital expenditures	(42,990,000)	(34,064,000)
Restricted cash, escrow deposits and other assets	(3,655,000)	2,143,000
Net cash used in investing activities	(2,487,471,000)	(541,080,000)
Cash flows from financing activities:
Borrowings on unsecured revolving credit facility	515,000,000	513,000,000
Payments on unsecured revolving credit facility	(528,000,000)	(704,000,000)
Proceeds from unsecured senior notes	900,000,000	347,725,000
Borrowings on unsecured term loans	0	200,000,000
Payments on unsecured term loans	0	(155,000,000)
Payments on secured mortgage loans	(75,444,000)	(98,453,000)
Deferred financing costs	(16,902,000)	(3,039,000)
Debt extinguishment costs	(10,391,000)	0
Security deposits	1,932,000	862,000
Proceeds from issuance of common stock	1,624,222,000	418,891,000
Repurchase and cancellation of common stock	(3,413,000)	(2,425,000)
Dividends paid	(145,877,000)	(116,655,000)
Distributions paid to noncontrolling interest of limited partners	(4,019,000)	(2,724,000)
Redemption of redeemable noncontrolling interest	0	(491,000)
Net cash provided by financing activities	2,257,108,000	397,691,000
Net change in cash and cash equivalents	(1,821,000)	4,868,000
Cash and cash equivalents - beginning of period	11,231,000	13,070,000
Cash and cash equivalents - end of period	9,410,000	17,938,000
Healthcare Trust of America Holdings, LP (HTALP)
Cash flows from operating activities:
Net income	22,105,000	30,191,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization and other	169,057,000	128,728,000
Share-based compensation expense	5,493,000	5,136,000
Bad debt expense	635,000	508,000
Impairment	5,093,000	0
Income from unconsolidated joint venture	(381,000)	0
Gain on sale of real estate, net	(3,000)	(4,212,000)
Loss on extinguishment of debt, net	11,192,000	3,022,000
Change in fair value of derivative financial instruments	(884,000)	2,144,000
Changes in operating assets and liabilities:
Receivables and other assets, net	(20,489,000)	(14,051,000)
Accounts payable and accrued liabilities	29,566,000	3,598,000
Prepaid rent and other liabilities	7,158,000	(6,807,000)
Net cash provided by operating activities	228,542,000	148,257,000
Cash flows from investing activities:
Investments in real estate	(2,357,570,000)	(532,527,000)
Investment in unconsolidated joint venture	(68,839,000)	0
Development of real estate	(19,163,000)	0
Proceeds from the sale of real estate	4,746,000	23,368,000
Capital expenditures	(42,990,000)	(34,064,000)
Restricted cash, escrow deposits and other assets	(3,655,000)	2,143,000
Net cash used in investing activities	(2,487,471,000)	(541,080,000)
Cash flows from financing activities:
Borrowings on unsecured revolving credit facility	515,000,000	513,000,000
Payments on unsecured revolving credit facility	(528,000,000)	(704,000,000)
Proceeds from unsecured senior notes	900,000,000	347,725,000
Borrowings on unsecured term loans	0	200,000,000
Payments on unsecured term loans	0	(155,000,000)
Payments on secured mortgage loans	(75,444,000)	(98,453,000)
Deferred financing costs	(16,902,000)	(3,039,000)
Debt extinguishment costs	(10,391,000)	0
Security deposits	1,932,000	862,000
Proceeds from issuance of general partner units	1,624,222,000	418,891,000
Repurchase and cancellation of general partner units	(3,413,000)	(2,425,000)
Distributions paid to general partner	(145,877,000)	(116,655,000)
Distributions paid to limited partners and redeemable noncontrolling interests	(4,019,000)	(2,724,000)
Redemption of redeemable noncontrolling interest	0	(491,000)
Net cash provided by financing activities	2,257,108,000	397,691,000
Net change in cash and cash equivalents	(1,821,000)	4,868,000
Cash and cash equivalents - beginning of period	11,231,000	13,070,000
Cash and cash equivalents - end of period	$ 9,410,000	$ 17,938,000

Organization and Description of

Organization and Description of Business	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Organization and Description of Business HTA, a Maryland corporation, and HTALP , a Delaware limited partnership, were incorporated or formed, as applicable, on April 20, 2006 . HTA operates as a REIT and is the general partner of HTALP , which is the operating partnership. As of September 30, 2017 , HTA owned a 98.0% partnership interest and other limited partners, including some of our directors, executive officers and their affiliates, owned the remaining partnership interest (including the LTIP Units) in HTALP . As the sole general partner of HTALP , HTA has the full, exclusive and complete responsibility for HTALP ’s day-to-day management and control. HTA operates in an umbrella partnership REIT structure in which HTALP and its subsidiaries hold substantially all of the assets. HTA’s only material asset is its ownership of partnership interests of HTALP . As a result, HTA does not conduct business itself, other than acting as the sole general partner of HTALP , issuing public equity from time to time and guaranteeing certain debts of HTALP . HTALP conducts the operations of the business and issues publicly-traded debt, but has no publicly-traded equity. HTA is the largest publicly-traded REIT focused on medical office buildings (“MOBs”) in the U.S. as measured by the gross leasable area (“GLA”) of our MOBs. HTA conducts substantially all of its operations through HTALP. We invest in MOBs that we believe will serve the future of healthcare delivery, and MOBs that are primarily located on health system campuses, near university medical centers, or in core community outpatient locations. We also focus on our key markets that have certain demographic and macro-economic trends and where we can utilize our institutional property management and leasing platform to generate strong tenant relationships and operating cost efficiencies. Our primary objective is to maximize stockholder value with disciplined growth through strategic investments that provide an attractive risk-adjusted return for our stockholders by consistently increasing our cash flow. In pursuing this objective, we: (i) seek internal growth through proactive asset management, leasing and property management oversight; (ii) target accretive acquisitions and developments of MOBs in markets with attractive demographics that complement our existing portfolio; and (iii) actively manage our balance sheet to maintain flexibility with conservative leverage. Additionally, from time to time we consider, on an opportunistic basis, significant portfolio acquisitions that we believe fit our core business and could enhance our existing portfolio. HTA has qualified to be taxed as a REIT for federal income tax purposes and intends to continue to be taxed as a REIT. Since 2006, we have invested $7.0 billion to create a portfolio of MOBs and other healthcare assets consisting of approximately 24.2 million square feet of GLA throughout the U.S. As of September 30, 2017 , our portfolio included $2.24 billion of investments, net of development credits received at closing, in connection with our acquisition of the Duke MOB business (the “Duke Acquisition”), which includes a 50% ownership interest in an unconsolidated joint venture for $68.8 million as of the date of acquisition. Our only remaining obligations related to the Duke Acquisition are the potential acquisition of a land parcel in Miami, FL and a single property in Texas that are each currently excluded from our purchase obligations due to current outstanding physical condition issues. As of September 30, 2017 , approximately 96% of our portfolio, based on GLA, was located on the campuses of, or aligned with, nationally or regionally recognized healthcare systems. Our portfolio is diversified geographically across 33 states, with no state having more than 19% of our total GLA as of September 30, 2017 . We are concentrated in 20 to 25 key markets that are experiencing higher economic and demographic trends than other markets, on average, that we expect will drive demand for MOBs. Approximately 92% of our portfolio, based on GLA, is located in the top 75 metropolitan statistical areas (“MSAs”) with Atlanta, Boston, Dallas, Houston and Tampa being our largest markets by investment. Our principal executive office is located at 16435 North Scottsdale Road, Suite 320, Scottsdale, Arizona, 85254.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies The summary of significant accounting policies presented below is designed to assist in understanding our condensed consolidated financial statements. Such condensed consolidated financial statements and the accompanying notes are the representations of our management, who are responsible for their integrity and objectivity. These accounting policies conform to U.S. generally accepted accounting principles (“GAAP”) in all material respects and have been consistently applied in preparing our accompanying condensed consolidated financial statements. Basis of Presentation Our accompanying condensed consolidated financial statements include our accounts and those of our subsidiaries and any consolidated variable interest entities (“VIEs”). All inter-company balances and transactions have been eliminated in the accompanying condensed consolidated financial statements. Interim Unaudited Financial Data Our accompanying condensed consolidated financial statements have been prepared by us in accordance with GAAP in conjunction with the rules and regulations of the SEC. Certain information and footnote disclosures required for annual financial statements have been condensed or excluded pursuant to SEC rules and regulations. Accordingly, our accompanying condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete financial statements. Our accompanying condensed consolidated financial statements reflect all adjustments, which are, in our opinion, of a normal recurring nature and necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods. Interim results of operations are not necessarily indicative of the results to be expected for the full year; such results may be less favorable for the full year. Our accompanying condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our 2016 Annual Report on Form 10-K. Principles of Consolidation The consolidated financial statements include the accounts of our subsidiaries and consolidated joint venture arrangements. The portions of the HTALP operating partnership not owned by us are presented as non-controlling interests in our consolidated balance sheets and statements of operations, consolidated statements of comprehensive income or loss, consolidated statements of equity, and consolidated statements of changes in partners’ capital. The portions of other joint venture arrangements not owned by us are presented as redeemable non-controlling interests in our consolidated balance sheets. In addition, as described in Note 1 - Organization and Description of Business , certain third parties have been issued OP Units in HTALP. Holders of OP Units are considered to be noncontrolling interest holders in HTALP and their ownership interests are reflected as equity in the consolidated balance sheets. Further, a portion of the earnings and losses of HTALP are allocated to noncontrolling interest holders based on their respective ownership percentages. Upon conversion of OP Units to common stock, any difference between the fair value of the common stock issued and the carrying value of the OP Units converted to common stock is recorded as a component of equity. As of September 30, 2017 and December 31, 2016 , there were approximately 4.1 million and 4.3 million , respectively, of OP Units issued and outstanding. VIEs are entities where investors lack sufficient equity at risk for the entity to finance its activities without additional subordinated financial support or where equity investors, as a group, lack one of the following: (i) the power to direct the activities that most significantly impact the entity’s economic performance; (ii) the obligation to absorb the expected losses of the entity; and (iii) the right to receive the expected returns of the entity. We consolidate our investment in VIEs when we determine that we are the primary beneficiary. A primary beneficiary is one that has both: (i) the power to direct the activities of the VIE that most significantly impacts the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The HTALP operating partnership and our other joint venture arrangements are VIEs because the limited partners in those partnerships, although entitled to vote on certain matters, do not possess kick-out rights or substantive participating rights. Additionally, we determined that we are the primary beneficiary of our VIEs. Accordingly, we consolidate our interests in the HTALP operating partnership and in our other joint venture arrangements. However, because we hold what is deemed a majority voting interest in the HTALP operating partnership and our other joint venture arrangements, it qualifies for the exemption from providing certain disclosure requirements associated with investments in VIEs. We will evaluate on an ongoing basis the need to consolidate entities based on the standards set forth in GAAP as described above. Unconsolidated Joint Ventures We account for our investments in unconsolidated joint ventures using the equity method of accounting because we have the ability to exercise significant influence, but not control, over the financial and operational policy decisions of the investments. Using the equity method of accounting, the initial investment is recognized at cost and subsequently adjusted for our share of the net income or loss and any distributions from the joint venture. As of September 30, 2017 , we had a 50% interest in one such investment with a carrying value, maximum exposure to risk, of $68.3 million , which is recorded in investment in unconsolidated joint venture in the accompanying condensed consolidated balance sheets. We record our share of net income (loss) in income (loss) from unconsolidated joint venture in the accompanying condensed consolidated statements of operations. For the three and nine months ended September 30, 2017 , we recognized income of $318,000 and $381,000 , respectively, from our unconsolidated joint venture. Investments in Real Estate Depreciation expense of buildings and improvements for the three months ended September 30, 2017 and 2016 was $49.8 million and $31.1 million , respectively. Depreciation expense of buildings and improvements for the nine months ended September 30, 2017 and 2016 was $121.5 million and $86.6 million , respectively. Recently Issued or Adopted Accounting Pronouncements The following table provides a brief description of recently adopted accounting pronouncements: Accounting Pronouncement Description Effective Date Effect on financial statements ASU 2017-01 Business Combinations: (Issued January 2017) ASU 2017-01 clarifies the definition of a business by adding guidance to assist entities evaluate whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting, including, but not limited to, acquisitions, disposals, goodwill and consolidation. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We adopted ASU 2017-01 as of January 1, 2017 on a prospective basis. We expect that the majority of our future investments in real estate will be accounted for as asset acquisitions under ASU 2017-01. The adoption of ASU 2017-01 will impact how we account for acquisition-related expenses and contingent consideration, which may result in lower acquisition-related expenses and eliminate fair value adjustments related to future contingent consideration arrangements. The following table provides a brief description of recently issued accounting pronouncements: Accounting Pronouncement Description Effective Date Effect on financial statements ASU 2014-09 Revenue from Contracts with Customers (Issued May 2014) ASU 2014-09 is a comprehensive new five-step model requiring a company to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (i.e., payment) to which the company expects to be entitled in exchange for those goods or services. Expanded quantitative and qualitative disclosures regarding revenue recognition will be required for contracts that are subject to ASU 2014-09. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach. In August 2015, the FASB deferred the effective date of ASU 2014-09 to the first interim period within annual reporting periods beginning after December 15, 2017 along with the right of early adoption as of the original effective date. We have identified all of our revenue streams and concluded rental income from leasing arrangements represents a substantial portion of our revenue and is specifically excluded from ASU 2014-09 and will be governed and evaluated with the anticipated adoption of ASU 2016-02 as described below. Upon adoption of ASU 2016-02, ASU 2014-09 may apply to executory costs and other components of revenue due under leases that are deemed to be non-lease components (such as common area maintenance and other reimbursement revenue), even when the revenue for such activities is not separately stipulated in the lease. In that case, the revenue from these items previously recognized on a straight-line basis under the current lease guidance would be recognized under the new revenue guidance as the related services are delivered. As a result, while total revenue recognized over time would not differ under the new guidance, the recognition pattern would be different. Under ASU 2014-09, revenue recognition for real estate sales is largely based on the transfer of control versus continuing involvement under the current guidance. Upon adoption, there will not be a material impact on our consolidated financial statements since we have historically disposed of the majority of our properties with no future controls or contingencies. We will adopt ASU 2014-09 effective January 1, 2018 using the modified retrospective approach. ASU 2016-02 Leases (Issued February 2016) ASU 2016-02 will supersede the existing guidance for lease accounting and states that companies will be required to recognize lease assets and lease liabilities on the balance sheet and disclose key information about leasing arrangements. ASU 2016-02 requires qualitative and quantitative disclosures to supplement the amounts recorded in the financial statements so that users can understand the nature of the entity’s leasing activities, including significant judgments and changes in judgments. Within ASU 2016-02 lessor accounting remained fairly unchanged. In adopting ASU 2016-02, companies will be required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. ASU 2016-02 is effective for the fiscal years beginning after December 15, 2018 with early adoption permitted. We are still evaluating the full impact of ASU 2016-02 on our consolidated financial statements, however, we will adopt ASU 2016-02 as of January 1, 2019 and anticipate that we will elect a practical expedient offered in ASU 2016-02 that allows an entity to not reassess the following upon adoption (elected as a group): (i) whether an expired or existing contract contains a lease arrangement; (ii) lease classification related to expired or existing lease arrangements; or (iii) whether costs incurred on expired or existing leases qualify as initial direct costs. As a result of the adoption, all new or amended leases for which we are the lessee, including corporate and ground leases, that are entered into on or after January 1, 2019, will be recorded on our consolidated financial statements as either financing leases or operating leases with a related right of use asset and lease liability. In addition, we expect that certain executory and non-lease components, such as common area maintenance, will need to be accounted for separately from the lease component of the lease. Lease components will continue to be recognized on a straight-line basis over the lease term and certain non-lease components will be accounted for under the new revenue recognition guidance in ASU 2014-09 as mentioned above. Accounting Pronouncement Description Effective Date Effect on financial statements ASU 2016-13 Financial Instruments Credit Losses: Measurement of Credit Losses on Financial Instruments (Issued June 2016) ASU 2016-13 is intended to improve financial reporting by requiring more timely recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. ASU 2016-13 requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected through an allowance for credit losses that is deducted from the amortized cost basis. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019 with early adoption permitted. We do not anticipate early adoption or there to be a material impact, however, we are evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements. ASU 2016-15 Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments (Issued August 2016) ASU 2016-15 clarifies the guidance on the classification of certain cash receipts and payments in the statement of cash flows to reduce diversity in practice with respect to: (i) debt prepayment or debt extinguishment costs; (ii) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (iii) contingent consideration payments made after a business combination; (iv) proceeds from the settlement of insurance claims; (v) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (vi) distributions received from equity method investees; (vii) beneficial interests in securitization transactions; and (viii) separately identifiable cash flows and application of the predominance principle. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We will adopt ASU 2016-15 during the fourth quarter of 2017 and apply the standard retrospectively for all periods presented. We will reclass cash payments related to debt prepayment and extinguishment costs from operating activities to financing activities. Based on our initial assessment the other listed provisions will not have a material impact on our consolidated financial statements and related notes resulting from the adoption of this standard. ASU 2016-18 Statement of Cash Flows: Restricted Cash (Issued November 2016) ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We will adopt ASU 2016-18 during the fourth quarter of 2017 and apply the standard retrospectively for all periods presented. Restricted cash and escrow deposits consist primarily of cash escrowed for real estate acquisitions, real estate taxes, property insurance and capital improvements. We will provide a reconciliation of the changes in cash and cash equivalents and restricted cash and escrow deposits within our consolidated balance sheets to the consolidated statement of cash flows. ASU 2017-05 Other Income: Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets (Issued February 2017) ASU 2017-05 defines an in-substance nonfinancial asset, unifies guidance related to partial sales of nonfinancial assets, eliminates rules specifically addressing the sales of real estate, removes exception to the financial asset derecognition model and clarifies the accounting for contributions of nonfinancial assets to joint ventures. ASU 2017-05 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We will adopt ASU 2017-05 as of January 1, 2018. We do not anticipate there to be a material impact on our consolidated financial statements, as we currently do not have this type of income. However, going forward we will continue to monitor any future impact. ASU 2017-09 Compensation - Stock Compensation (Topic 718): Clarifying the Scope of Modification (Issued May 2017) ASU 2017-09 amends the scope of modification accounting for share-based payment arrangements and provides guidance on the types of changes to the terms and conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We will adopt ASU 2017-09 as of January 1, 2018. We do not anticipate there to be a material impact on our consolidated financial statements. ASU 2017-12 Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (Issued August 2017) ASU 2017-12 expands and refines hedge accounting for both financial (e.g., interest rate) and non-financial risk components, aligns the recognition and presentation of the effects of hedging instruments and hedge items in the financial statements, and includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. ASU 2017-12 is effective for fiscal years beginning after December 15, 2018 with early adoption permitted. We do not anticipate early adoption, however, we are evaluating the impact of adopting ASU 2017-12 on our consolidated financial statements.

Investments in Real Estate

Investments in Real Estate	9 Months Ended
	Sep. 30, 2017
Investments [Abstract]
Investments in Real Estate	Investments in Real Estate Our investments, including the Duke Acquisition, brings our total investments for the nine months ended September 30, 2017 , to an aggregate purchase price of $2.7 billion . As part of these investments, we incurred $17.2 million of costs attributable to these investments, which were capitalized in accordance with the adoption of ASU 2017-01 during the nine months ended September 30, 2017 . In addition, as part of an acquisition, we issued 20,687 OP Units with a market value at the time of issuance of $0.6 million . The allocations for these investments, in which we own a controlling financial interest, are set forth below in the aggregate for the nine months ended September 30, 2017 and 2016 , respectively (in thousands): Nine Months Ended September 30, 2017 2016 Land $ 93,064 $ 77,949 Building and improvements 2,336,544 505,138 In place leases 187,890 50,997 Below market leases (27,817 ) (12,790 ) Above market leases 11,718 4,413 Below market leasehold interests 54,252 4,188 Above market leasehold interests (8,978 ) (50 ) Below market debt — 360 Interest rate swaps — (779 ) Net assets acquired 2,646,673 629,426 Other, net (1) 60,781 3,540 Aggregate purchase price $ 2,707,454 $ 632,966 (1) For the nine months ended September 30, 2017, other, net, consisted primarily of capital expenditures and tenant improvements received as credits at the time of acquisition. Subsequent to September 30, 2017 , we completed an investment with a purchase price of $8.3 million . As part of the acquisition, we issued to the seller as a part of the acquisition consideration a total of 16,972 OP Units with a market value at the time of issuance of $0.5 million . The purchase price of this investment was subject to certain post-closing adjustments. Due to the recent timing of this investment, we have not yet completed our purchase price allocation with respect to this investment and, therefore, we cannot provide disclosures at this time similar to those set forth above in Note 3 - Investments in Real Estate to our condensed consolidated financial statements. The acquired intangible assets and liabilities referenced above had weighted average lives of the following for the nine months ended September 30, 2017 and 2016 , respectively (in years): Nine Months Ended September 30, 2017 2016 Acquired intangible assets 20.6 9.1 Acquired intangible liabilities 19.9 8.3

Impairment and Dispositions

Impairment and Dispositions	9 Months Ended
	Sep. 30, 2017
Disposal Group, Not Discontinued Operation, Disposal Disclosures [Abstract]
Impairment and Dispositions	Impairment and Dispositions During the nine months ended September 30, 2017 , we completed the disposition of an MOB located in Texas for a gross sales price of $5.0 million , representing approximately 48,000 square feet of GLA. In addition, during the nine months ended September 30, 2017 , we recorded impairment charges of $5.1 million related to one MOB located in Massachusetts. During the nine months ended September 30, 2016 , we completed a disposition of four senior care facilities for an aggregate gross sales price of $26.5 million . During the nine months ended September 30, 2016 , we recorded no impairment charges.

Intangible Assets and Liabiliti

Intangible Assets and Liabilities	9 Months Ended
	Sep. 30, 2017
Identified Intangibles, Net [Abstract]
Intangible Assets and Liabilities	Intangible Assets and Liabilities Intangible assets and liabilities consisted of the following as of September 30, 2017 and December 31, 2016 , respectively (in thousands, except weighted average remaining amortization): September 30, 2017 December 31, 2016 Balance Weighted Average Remaining Amortization in Years Balance Weighted Average Remaining Amortization in Years Assets: In place leases $ 478,052 9.7 $ 294,597 9.7 Tenant relationships 170,539 10.7 172,974 10.6 Above market leases 39,724 6.3 28,401 6.3 Below market leasehold interests 92,362 63.4 38,136 60.4 780,677 534,108 Accumulated amortization (299,398 ) (256,305 ) Total $ 481,279 19.2 $ 277,803 16.1 Liabilities: Below market leases $ 61,788 14.7 $ 34,370 18.6 Above market leasehold interests 20,610 50.3 11,632 53.0 82,398 46,002 Accumulated amortization (12,546 ) (8,946 ) Total $ 69,852 24.9 $ 37,056 28.5 The following is a summary of the net intangible amortization for the three and nine months ended September 30, 2017 and 2016 , respectively (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Amortization recorded against rental income related to above and (below) market leases $ (108 ) $ (115 ) $ (371 ) $ 202 Rental expense related to above and (below) market leasehold interests 322 118 617 321 Amortization expense related to in place leases and tenant relationships 18,757 15,266 45,944 39,483

Receivables and Other Assets

Receivables and Other Assets	9 Months Ended
	Sep. 30, 2017
Receivables and Other Assets [Abstract]
Receivables and Other Assets	Receivables and Other Assets Receivables and other assets consisted of the following as of September 30, 2017 and December 31, 2016 , respectively (in thousands): September 30, 2017 December 31, 2016 Tenant receivables, net $ 14,417 $ 8,722 Other receivables, net 10,161 9,233 Deferred financing costs, net 8,190 4,198 Deferred leasing costs, net 23,794 20,811 Straight-line rent receivables, net 83,133 74,052 Prepaid expenses, deposits, equipment and other, net 65,383 55,904 Derivative financial instruments - interest rate swaps 952 541 Total $ 206,030 $ 173,461 The following is a summary of the amortization of deferred leasing costs and financing costs for the three and nine months ended September 30, 2017 and 2016 , respectively (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Amortization expense related to deferred leasing costs $ 1,445 $ 1,224 $ 4,179 $ 3,368 Interest expense related to deferred financing costs 398 331 1,061 994

Debt

Debt	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Debt	Debt Debt consisted of the following as of September 30, 2017 and December 31, 2016 , respectively (in thousands): September 30, 2017 December 31, 2016 Unsecured revolving credit facility $ 75,000 $ 88,000 Unsecured term loans 500,000 500,000 Unsecured senior notes 1,850,000 950,000 Fixed rate mortgages loans 415,853 204,562 Variable rate mortgages loans 38,169 38,904 2,879,022 1,781,466 Deferred financing costs, net (16,552 ) (9,527 ) Discount, net (5,712 ) (3,034 ) Total $ 2,856,758 $ 1,768,905 Unsecured Credit Agreement Unsecured Revolving Credit Facility due 2022 On July 27, 2017, HTALP entered into an amended and restated $1.3 billion unsecured credit agreement (the “Unsecured Credit Agreement”) which increased the amount available under the unsecured revolving credit facility to $1.0 billion and extended the maturities of the unsecured revolving credit facility to June 30, 2022 and for the $300.0 million unsecured term loan referenced below until February 1, 2023 . The maximum principal amount of the Unsecured Credit Agreement may be increased by up to $750.0 million , subject to certain conditions, for a total principal amount of $2.05 billion . Borrowings under the unsecured revolving credit facility accrue interest at a rate equal to adjusted LIBOR , plus a margin ranging from 0.83% to 1.55% per annum based on our credit rating. We also pay a facility fee ranging from 0.13% to 0.30% per annum on the aggregate commitments under the unsecured revolving credit facility. As of September 30, 2017 , the margin associated with our borrowings was 1.00% per annum and the facility fee was 0.20% per annum. Unsecured Term Loan due 2023 On July 27, 2017, we entered into an amended and restated Unsecured Credit Agreement as noted above. As part of this agreement, we obtained a $300.0 million unsecured term loan that was guaranteed by us with a maturity date of February 1, 2023 . Borrowings under this unsecured term loan accrue interest equal to adjusted LIBOR , plus a margin ranging from 0.90% to 1.75% per annum based on our credit rating. The margin associated with our borrowings as of September 30, 2017 was 1.10% per annum. Including the impact of the interest rate swaps associated with our unsecured term loan, the interest rate was 2.40% per annum, based on our current credit rating. As of September 30, 2017 , HTALP had $300.0 million under this unsecured term loan outstanding. Bridge Loan Facility In connection with the Duke Acquisition, in May 2017, we entered into a senior unsecured bridge loan facility (the “Bridge Loan Facility”) which provided to us up to $2.47 billion , less the aggregate amount of net proceeds from debt or equity capital raises or a senior term loan facility. The Bridge Loan Facility was made available to us on the closing of the Duke Acquisition and was scheduled to mature 364 days from the closing. In June 2017, we terminated the Bridge Loan Facility and no proceeds were used because we elected to fund the Duke Acquisition through other equity and debt offerings. In connection with the execution and subsequent termination of the Bridge Loan Facility, we incurred $10.4 million in related fees, which we recorded in income (loss) on extinguishment of debt in the accompanying condensed consolidated statements of operations. $200.0 Million Unsecured Term Loan due 2023 As of September 30, 2017 , HTALP had a $200.0 million unsecured term loan outstanding, which matures on September 26, 2023 . Borrowings under the unsecured term loan accrue interest at a rate equal to LIBOR, plus a margin ranging from 1.50% to 2.45% per annum based on our credit rating. The margin associated with our borrowings as of September 30, 2017 was 1.65% per annum. HTALP had interest rate swaps in place that fixed the interest rate at 2.93% per annum, based on our current credit rating. $300.0 Million Unsecured Senior Notes due 2021 As of September 30, 2017 , HTALP had $300.0 million of unsecured senior notes outstanding that are guaranteed by us. These unsecured senior notes are registered under the Securities Act of 1933, as amended (the “Securities Act”), bear interest at 3.38% per annum and are payable semi-annually. Additionally, these unsecured senior notes were offered at 99.21% of the principal amount thereof, with an effective yield to maturity of 3.50% per annum. As of September 30, 2017 , HTALP had $300.0 million of these unsecured senior notes outstanding that mature on July 15, 2021. $400.0 Million Unsecured Senior Notes due 2022 In June 2017, in connection with the Duke Acquisition and the $500.0 million unsecured senior notes due 2027 referenced below, HTALP issued $400.0 million of unsecured senior notes that are guaranteed by us. These unsecured senior notes are registered under the Securities Act, bear interest at 2.95% per annum and are payable semi-annually. Additionally, these unsecured senior notes were offered at 99.94% of the principal amount thereof, with an effective yield to maturity of 2.96% per annum. As of September 30, 2017 , HTALP had $400.0 million of these unsecured senior notes outstanding that mature on July 1, 2022. $300.0 Million Unsecured Senior Notes due 2023 As of September 30, 2017 , HTALP had $300.0 million of unsecured senior notes outstanding that are guaranteed by us. These unsecured senior notes are registered under the Securities Act, bear interest at 3.70% per annum and are payable semi-annually. Additionally, these unsecured senior notes were offered at 99.19% of the principal amount thereof, with an effective yield to maturity of 3.80% per annum. As of September 30, 2017 , HTALP had $300.0 million of these unsecured senior notes outstanding that mature on April 15, 2023. $350.0 Million Unsecured Senior Notes due 2026 As of September 30, 2017 , HTALP had $350.0 million of unsecured senior notes outstanding that are guaranteed by us. These unsecured senior notes are registered under the Securities Act, bear interest at 3.50% per annum and are payable semi-annually. Additionally, these unsecured senior notes were offered at 99.72% of the principal amount thereof, with an effective yield to maturity of 3.53% per annum. As of September 30, 2017 , HTALP had $350.0 million of these unsecured senior notes outstanding that mature on August 1, 2026. $500.0 Million Unsecured Senior Notes due 2027 In June 2017, in connection with the Duke Acquisition and the $400.0 million unsecured senior notes due 2022 referenced above, HTALP issued $500.0 million of unsecured senior notes that are guaranteed by us. These unsecured senior notes are registered under the Securities Act, bear interest at 3.75% per annum and are payable semi-annually. Additionally, these unsecured senior notes were offered at 99.49% of the principal amount thereof, with an effective yield to maturity of 3.81% per annum. As of September 30, 2017 , HTALP had $500.0 million of these unsecured senior notes outstanding that mature on July 1, 2027. Fixed and Variable Rate Mortgages In June 2017, as part of the Duke Acquisition, we were required by the seller to execute as the borrower for a part of the purchase price a senior secured first lien loan, subject to customary non-recourse carve-outs, in the amount of $286.0 million (the “Promissory Note”). The Promissory Note bears interest at 4.0% per annum and is payable in three equal payments maturing on January 10, 2020 and is guaranteed by us. As of September 30, 2017 , HTALP and its subsidiaries had fixed and variable rate mortgages loans with interest rates ranging from 2.70% to 6.39% per annum and a weighted average interest rate of 4.31% per annum. Including the impact of the interest rate swap associated with our variable rate mortgages, the weighted average interest rate was 4.46% per annum. Future Debt Maturities The following table summarizes the debt maturities and scheduled principal repayments of our indebtedness as of September 30, 2017 (in thousands): Year Amount Remainder of 2017 $ 1,166 2018 100,827 2019 105,940 2020 144,892 2021 303,933 Thereafter 2,222,264 Total $ 2,879,022 Deferred Financing Costs As of September 30, 2017 , the future amortization of our deferred financing costs is as follows (in thousands): Year Amount Remainder of 2017 $ 618 2018 2,821 2019 2,826 2020 2,804 2021 2,610 Thereafter 4,873 Total $ 16,552 We are required by the terms of our applicable loan agreements to meet various affirmative and negative covenants that we believe are customary for these types of facilities, such as limitations on the incurrence of debt by us and our subsidiaries that own unencumbered assets, limitations on the nature of HTALP ’s business, and limitations on distributions by HTALP and its subsidiaries that own unencumbered assets. Our loan agreements also impose various financial covenants on us, such as a maximum ratio of total indebtedness to total asset value, a minimum ratio of EBITDA to fixed charges, a minimum tangible net worth covenant, a maximum ratio of unsecured indebtedness to unencumbered asset value, rent coverage ratios and a minimum ratio of unencumbered net operating income to unsecured interest expense. As of September 30, 2017 , we believe that we were in compliance with all such financial covenants and reporting requirements. In addition, certain of our loan agreements include events of default provisions that we believe are customary for these types of facilities, including restricting us from making dividend distributions to our stockholders in the event we are in default thereunder, except to the extent necessary for us to maintain our REIT status.

Derivative Financial Instrument

Derivative Financial Instruments and Hedging Activities	9 Months Ended
	Sep. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments and Hedging Activities	Derivative Financial Instruments and Hedging Activities Risk Management Objective of Using Derivative Financial Instruments We may use derivative financial instruments, including interest rate swaps, caps, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with our borrowings. The principal objective of such arrangements is to minimize the risks and/or costs associated with our operating and financial structure as well as to hedge specific anticipated transactions. We do not intend to utilize derivatives for speculative or other purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, we only enter into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which we and our affiliates may also have other financial relationships. We do not anticipate that any of the counterparties will fail to meet their obligations. We record counterparty credit risk valuation adjustments on interest rate swap derivative assets in order to properly reflect the credit quality of the counterparty. In addition, our fair value of interest rate swap derivative liabilities is adjusted to reflect the impact of our credit quality. Cash Flow Hedges of Interest Rate Risk Our objectives in using interest rate derivatives are to add stability to interest expense and to manage our exposure to interest rate movements. To accomplish this objective, we primarily use interest rate swaps and treasury locks as part of our interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable rate amounts from a counterparty in exchange for us making fixed rate payments over the life of the agreements without exchange of the underlying notional amount. A treasury lock is a synthetic forward sale of a U.S. treasury note, which is settled in cash based upon the difference between an agreed upon treasury rate and the prevailing treasury rate at settlement. Such treasury locks are entered into to effectively fix the treasury component of an upcoming debt issuance. The effective portion of changes in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive income in the accompanying condensed consolidated balance sheets and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. During the three and nine months ended September 30, 2017 , such derivatives were used to hedge the variable cash flows associated with variable rate debt. The ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. During the three and nine months ended September 30, 2017 , we recorded approximately $4,000 and $31,000 , respectively, of hedge ineffectiveness in earnings. We designated our derivative financial instruments as cash flow hedges in March 2017 . During the nine months ended September 30, 2017 , we entered into and settled two treasury locks designated as cash flow hedges with an aggregate notional amount of $250.0 million to hedge future fixed rate debt issuances, which fixed the 10 -year swap rates at an average rate of 2.26% per annum. Upon settlement of these contracts during the nine months ended September 30, 2017 , we paid and reported a loss of $0.7 million which was recorded in accumulated other comprehensive loss in our accompanying condensed consolidated statements of comprehensive income (loss) and a gain of $25,000 which was recorded in the change in fair value of our derivative financial instruments in our accompanying condensed consolidated statements of operations. Amounts reported in accumulated other comprehensive income in the accompanying condensed consolidated balance sheets related to derivatives will be reclassified to interest expense as interest payments are made on our variable rate debt. During the next twelve months, we estimate that an additional $0.4 million will be reclassified from other comprehensive income in the accompanying condensed consolidated balance sheets as an increase to interest related to derivative financial instruments in the accompanying condensed consolidated statements of operations. As of September 30, 2017 , we had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk (in thousands, except number of instruments): Interest Rate Swaps September 30, 2017 Number of instruments 5 Notional amount $ 189,751 The table below presents the fair value of our derivative financial instruments designated as a hedge as well as our classification in the accompanying condensed consolidated balance sheets as of September 30, 2017 (in thousands). In March 2017 , we designated our derivative financial instruments as cash flow hedges. As such, prior to March 2017 we did not have derivatives designated as hedging instruments. Asset Derivatives Liability Derivatives Fair Value at: Fair Value at: Derivatives Designated as Hedging Instruments: Balance Sheet Location September 30, 2017 December 31, 2016 Balance Sheet Location September 30, 2017 December 31, 2016 Interest rate swaps Receivables and other assets $ 952 $ — Derivative financial instruments $ 1,441 $ — The tables below present the gain or loss recognized on our derivative financial instruments designated as hedges as well as our classification in the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2017 and 2016 (in thousands). In March 2017 , we designated our derivative financial instruments as cash flow hedges. As such, prior to March 2017 we did not have derivatives designated as hedging instruments. Gain (Loss) Recognized in OCI on Derivative (Effective Portion): Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion): Gain (Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing): Three Months Ended September 30, Three Months Ended September 30, Three Months Ended September 30, Derivatives Cash Flow Hedging Relationships: 2017 2016 Statement of Operations Location 2017 2016 Statement of Operations Location 2017 2016 Interest rate swaps $ 9 $ — Interest related to derivative financial instruments $ (196 ) $ — Interest related to derivative financial instruments $ (4 ) $ — Gain (Loss) Recognized in OCI on Derivative (Effective Portion): Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion): Gain (Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing): Nine Months Ended September 30, Nine Months Ended September 30, Nine Months Ended September 30, Derivatives Cash Flow Hedging Relationships: 2017 2016 Statement of Operations Location 2017 2016 Statement of Operations Location 2017 2016 Interest rate swaps $ (1,196 ) $ — Interest related to derivative financial instruments $ (565 ) — Interest related to derivative financial instruments $ (31 ) $ — Non-Designated Hedges Derivatives not designated as hedges are not speculative and are used to manage our exposure to interest rate movements and other identified risks, but do not meet the strict hedge accounting requirements of ASC 815 - Derivatives and Hedging. Changes in the fair value of derivatives not designated in hedging relationships are recorded directly in earnings. Changes in the fair value of derivatives not designated in hedging relationships are recorded directly to gain or loss on change in fair value of derivative financial instruments in the accompanying condensed consolidated statements of operations. For the nine months ended September 30, 2017 , we recorded a gain on change in fair value of derivative financial instruments of $0.9 million . For the three months ended September 30, 2017 , we did no t record a gain or loss on change in fair value of derivative financial instruments as we did not have any derivative financial instruments classified as non-designated hedges. The table below presents the fair value of our derivative financial instruments not designated as hedges as well as our classification in the accompanying condensed consolidated balance sheets as of December 31, 2016 (in thousands). In March 2017 , we designated our derivative financial instruments as cash flow hedges. As such, as of March 2017 we did not have derivatives not designated as hedging instruments. Asset Derivatives Liability Derivatives Fair Value at: Fair Value at: Derivatives NOT Designated as Hedging Instruments: Balance Sheet Location September 30, 2017 December 31, 2016 Balance Sheet Location September 30, 2017 December 31, 2016 Interest rate swaps Receivables and other assets $ — $ 541 Derivative financial instruments $ — $ 1,920 Tabular Disclosure of Offsetting Derivatives The table below sets forth the net effects of offsetting and net presentation of our derivatives as of September 30, 2017 and December 31, 2016 , respectively (in thousands). The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets or liabilities are presented in the consolidated balance sheets. Offsetting of Derivative Assets Gross Amounts of Recognized Assets Gross Amounts in the Consolidated Balance Sheets Net Amounts of Assets Presented in the Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount September 30, 2017 $ 952 $ — $ 952 $ — $ — $ 952 December 31, 2016 541 — 541 — — 541 Offsetting of Derivative Liabilities Gross Amounts of Recognized Liabilities Gross Amounts in the Consolidated Balance Sheets Net Amounts of Liabilities Presented in the Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount September 30, 2017 $ 1,441 $ — $ 1,441 $ — $ — $ 1,441 December 31, 2016 1,920 — 1,920 — — 1,920 Credit Risk Related Contingent Features We have agreements with each of our derivative counterparties that contain a provision that if we default on any of our indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender, then we could also be declared in default on our derivative obligations. We also have agreements with each of our derivative counterparties that incorporate provisions from our indebtedness with a lender affiliate of the derivative counterparty requiring it to maintain certain minimum financial covenant ratios on our indebtedness. Failure to comply with the covenant provisions would result in us being in default on any derivative instrument obligations covered by these agreements. As of September 30, 2017 , the fair value of derivatives in a net liability position, including accrued interest, but excluding any adjustment for nonperformance risk related to these agreements, was $1.5 million . As of September 30, 2017 , we have not posted any collateral related to these agreements and we were not in breach of any of the provisions of these agreements. If we had breached any of these provisions of these agreements, we could have been required to settle our obligations under these agreements at an aggregate termination value of $1.5 million at September 30, 2017 .

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Litigation We engage in litigation from time to time with various parties as a routine part of our business, including tenant defaults. However, we are not presently subject to any material litigation nor, to our knowledge, is any material litigation threatened against us, which if determined unfavorably to us, would have a material effect on our condensed consolidated financial position, results of operations or cash flows. Environmental Matters We follow the policy of monitoring our properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at our properties, we are not currently aware of any environmental liability with respect to our properties that would have a material effect on our condensed consolidated financial position, results of operations or cash flows. Further, we are not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability at our properties that we believe would require additional disclosure or the recording of a loss contingency. Other Our other commitments and contingencies include the usual obligations of real estate owners and operators in the normal course of business. In our opinion, these matters are not expected to have a material effect on our condensed consolidated financial position, results of operations or cash flows.

Stockholders' Equity and Partne

Stockholders' Equity and Partners' Capital	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Stockholders' Equity and Partners' Capital	Stockholders’ Equity and Partners’ Capital HTALP ’s operating partnership agreement provides that it will distribute cash flow from operations and net sale proceeds to its partners in accordance with their overall ownership interests at such times and in such amounts as the general partner determines. Dividend distributions are made such that a holder of one OP Unit in HTALP will receive distributions from HTALP in an amount equal to the dividend distributions paid to the holder of one share of our common stock. In addition, for each share of common stock issued or redeemed by us, HTALP issues or redeems a corresponding number of OP Units. During the nine months ended September 30, 2017 , we issued $1.7 billion of equity at an average price of $28.70 per share. Common Stock Offerings In September 2017, we entered into new equity distribution agreements with our various sales agents with respect to our at-the-market (“ATM”) offering program of common stock with an aggregate sales amount of up to $500.0 million . We contemporaneously terminated our prior ATM equity distribution agreements. During the nine months ended September 30, 2017 , and under the previous ATM, we issued and sold 3,998,000 shares of our common stock for $125.7 million of gross proceeds at an average price of $31.45 per share. As of September 30, 2017 , $500.0 million remained available for issuance by us under the September 2017 ATM. During the nine months ended September 30, 2017 , we, in connection with the Duke Acquisition, completed an underwritten public offering of 54,625,000 shares of our common stock for $1.6 billion of gross proceeds at a price of $28.50 per share. Subsequent to September 30, 2017 , we issued $200.0 million of common stock under the ATM, including $75.0 million on a forward basis which will be issued over the next six months. Common Unit Offerings During the nine months ended September 30, 2017 , we issued 20,687 OP Units in HTALP for approximately $0.6 million in connection with an acquisition transaction. Subsequent to September 30, 2017 , as part of an acquisition, we issued to the seller as a part of the acquisition consideration 16,972 OP Units in HTALP for approximately $0.5 million . Common Stock Dividends See our accompanying condensed consolidated statements of operations for the dividends declared during the three and nine months ended September 30, 2017 and 2016 . On October 24, 2017 , our Board of Directors announced a quarterly dividend of $0.305 per share of common stock. The dividends are to be paid on January 9, 2018 to stockholders of record of our common stock on January 2, 2018 . Incentive Plan Our Amended and Restated 2006 Incentive Plan (the “Plan”) permits the grant of incentive awards to our employees, officers, non-employee directors and consultants as selected by our Board of Directors. The Plan authorizes us to grant awards in any of the following forms: options; stock appreciation rights; restricted stock; restricted or deferred stock units; performance awards; dividend equivalents; other stock-based awards, including units in HTALP ; and cash-based awards. Subject to adjustment as provided in the Plan, the aggregate number of awards reserved and available for issuance under the Plan is 5,000,000 shares. As of September 30, 2017 , there were 1,689,585 awards available for grant under the Plan. LTIP Units Awards under the LTIP consist of Series C units in HTALP and were subject to the achievement of certain performance and market conditions in order to vest. O nce vested, the Series C units were converted into common units of HTALP , which may be converted into shares of our common stock. The LTIP awards were fully expensed or forfeited in 2015. Restricted Common Stock For the three and nine months ended September 30, 2017 , we recognized compensation expense of $1.7 million and $5.5 million , respectively. For the three and nine months ended September 30, 2016 , we recognized compensation expense of $2.1 million and $5.1 million , respectively. Compensation expense for the three and nine months ended September 30, 2017 and 2016 were recorded in general and administrative expenses in the accompanying condensed consolidated statements of operations. As of September 30, 2017 , we had $9.1 million of unrecognized compensation expense, net of estimated forfeitures, which we will recognize over a remaining weighted average period of 1.8 years. The following is a summary of our restricted common stock activity as of September 30, 2017 and 2016 , respectively: September 30, 2017 September 30, 2016 Restricted Common Stock Weighted Average Grant Date Fair Value Restricted Common Stock Weighted Average Grant Date Fair Value Beginning balance 640,870 $ 27.36 487,850 $ 23.13 Granted 292,109 29.75 417,110 29.82 Vested (278,821 ) 25.31 (236,749 ) 23.27 Forfeited (58,384 ) 28.86 (24,391 ) 25.93 Ending balance 595,774 $ 29.39 643,820 $ 27.35

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments Financial Instruments Reported at Fair Value - Recurring The table below presents our assets and liabilities measured at fair value on a recurring basis as of September 30, 2017 , aggregated by the applicable level in the fair value hierarchy (in thousands): Level 1 Level 2 Level 3 Total Assets: Derivative financial instruments $ — $ 952 $ — $ 952 Liabilities: Derivative financial instruments $ — $ 1,441 $ — $ 1,441 The table below presents our assets and liabilities measured at fair value on a recurring basis as of December 31, 2016 , aggregated by the applicable level in the fair value hierarchy (in thousands): Level 1 Level 2 Level 3 Total Assets: Derivative financial instruments $ — $ 541 $ — $ 541 Liabilities: Derivative financial instruments $ — $ 1,920 $ — $ 1,920 Financial Instruments Reported at Fair Value - Non-Recurring The table below presents our assets measured at fair value on a non-recurring basis as of September 30, 2017 , aggregated by the applicable level in the fair value hierarchy (in thousands): Level 1 Level 2 Level 3 Total Assets: MOB (1) $ — $ 1,423 $ — $ 1,423 (1) During the nine months ended September 30, 2017, we recognized a $5.1 million impairment charge to one MOB. The estimated fair value as of September 30, 2017 for this MOB was based upon real estate market comparables. The table below presents our assets measured at fair value on a non-recurring basis as of December 31, 2016 , aggregated by the applicable level in the fair value hierarchy (in thousands): Level 1 Level 2 Level 3 Total Assets: MOB (1) $ — $ 8,191 $ — $ 8,191 (1) During the year ended December 31, 2016, we recognized impairment charges of $1.3 million and $1.8 million to the carrying value of two MOBs. The estimated fair value as of December 31, 2016 for these two MOBs was based upon a pending sales agreement and real estate market comparables. There have been no transfers of assets or liabilities between levels. We will record any such transfers at the end of the reporting period in which a change of event occurs that results in a transfer. Although we have determined that the majority of the inputs used to value our interest rate swap derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with these instruments utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by us and our counterparties. However, we have assessed the significance of the impact of the credit valuation adjustments on the overall valuation of our interest rate swap derivative positions and have determined that the credit valuation adjustments are not significant to their overall valuation. As a result, we have determined that our interest rate swap derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy. Financial Instruments Disclosed at Fair Value We consider the carrying values of cash and cash equivalents, tenant and other receivables, restricted cash and escrow deposits and accounts payable, and accrued liabilities, to approximate fair value for these financial instruments because of the short period of time between origination of the instruments and their expected realization. All of these financial instruments are considered Level 2. The fair value of debt is estimated using borrowing rates available to us with similar terms and maturities, which is considered a Level 2 input. As of September 30, 2017 , the fair value of the debt was $2,913.3 million compared to the carrying value of $2,856.8 million . As of December 31, 2016 , the fair value of the debt was $1,784.0 million compared to the carrying value of $1,768.9 million .

Per Share Data of HTA

Per Share Data of HTA	9 Months Ended
	Sep. 30, 2017
HTA, Inc.
Earnings Per Share
Per Share Data of HTA	Per Share Data of HTA We include unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents as “participating securities” pursuant to the two-class method. The resulting classes are our common stock and restricted stock. For the three and nine months ended September 30, 2017 and 2016 , all of our earnings were distributed and the calculated earnings per share amount would be the same for all classes. The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per share of HTA for the three and nine months ended September 30, 2017 and 2016 , respectively (in thousands, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Numerator: Net income $ 13,957 $ 6,639 $ 22,105 $ 30,191 Net income attributable to noncontrolling interests (194 ) (212 ) (715 ) (830 ) Net income attributable to common stockholders $ 13,763 $ 6,427 $ 21,390 $ 29,361 Denominator: Weighted average shares outstanding - basic 200,674 138,807 173,189 134,905 Dilutive shares 4,121 4,331 4,221 3,409 Weighted average shares outstanding - diluted 204,795 143,138 177,410 138,314 Earnings per common share - basic Net income attributable to common stockholders $ 0.07 $ 0.05 $ 0.12 $ 0.22 Earnings per common share - diluted Net income attributable to common stockholders $ 0.07 $ 0.04 $ 0.12 $ 0.21

Per Unit Data of HTALP

Per Unit Data of HTALP	9 Months Ended
	Sep. 30, 2017
Healthcare Trust of America Holdings, LP (HTALP)
Earnings Per Share
Per Unit Data of HTALP	Per Unit Data of HTALP The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per unit of HTALP for the three and nine months ended September 30, 2017 and 2016 , respectively (in thousands, except per unit data): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Numerator: Net income $ 13,957 $ 6,639 $ 22,105 $ 30,191 Net income attributable to noncontrolling interests (28 ) (1 ) (80 ) (28 ) Net income attributable to common unitholders $ 13,929 $ 6,638 $ 22,025 $ 30,163 Denominator: Weighted average units outstanding - basic 204,795 143,137 177,410 138,314 Dilutive units — — — — Weighted average units outstanding - diluted 204,795 143,137 177,410 138,314 Earnings per common unit - basic: Net income attributable to common unitholders $ 0.07 $ 0.05 $ 0.12 $ 0.22 Earnings per common unit - diluted: Net income attributable to common unitholders $ 0.07 $ 0.05 $ 0.12 $ 0.22

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Sep. 30, 2017
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	Supplemental Cash Flow Information The following is the supplemental cash flow information for the nine months ended September 30, 2017 and 2016 , respectively (in thousands): Nine Months Ended September 30, 2017 2016 Supplemental Disclosure of Cash Flow Information: Interest paid $ 51,066 $ 39,321 Income taxes paid 997 934 Supplemental Disclosure of Noncash Investing and Financing Activities: Accrued capital expenditures $ 4,185 $ 2,868 Debt and interest rate swaps assumed and entered into in connection with an acquisition 286,000 21,156 Dividend distributions declared, but not paid 62,494 43,530 Issuance of operating partnership units in connection with an acquisition 610 71,754 Note receivable included in the consideration of a disposition — 3,000 Note receivable retired in connection with an acquisition 2,494 — Redeemable noncontrolling interest assumed in connection with an acquisition — 5,449 Redemption of noncontrolling interest 5,694 5,709

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation Our accompanying condensed consolidated financial statements include our accounts and those of our subsidiaries and any consolidated variable interest entities (“VIEs”). All inter-company balances and transactions have been eliminated in the accompanying condensed consolidated financial statements.
Interim Unaudited Financial Data	Interim Unaudited Financial Data Our accompanying condensed consolidated financial statements have been prepared by us in accordance with GAAP in conjunction with the rules and regulations of the SEC. Certain information and footnote disclosures required for annual financial statements have been condensed or excluded pursuant to SEC rules and regulations. Accordingly, our accompanying condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete financial statements. Our accompanying condensed consolidated financial statements reflect all adjustments, which are, in our opinion, of a normal recurring nature and necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods. Interim results of operations are not necessarily indicative of the results to be expected for the full year; such results may be less favorable for the full year. Our accompanying condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our 2016 Annual Report on Form 10-K.
Principles of Consolidation and Unconsolidated Joint Ventures	Principles of Consolidation The consolidated financial statements include the accounts of our subsidiaries and consolidated joint venture arrangements. The portions of the HTALP operating partnership not owned by us are presented as non-controlling interests in our consolidated balance sheets and statements of operations, consolidated statements of comprehensive income or loss, consolidated statements of equity, and consolidated statements of changes in partners’ capital. The portions of other joint venture arrangements not owned by us are presented as redeemable non-controlling interests in our consolidated balance sheets. In addition, as described in Note 1 - Organization and Description of Business , certain third parties have been issued OP Units in HTALP. Holders of OP Units are considered to be noncontrolling interest holders in HTALP and their ownership interests are reflected as equity in the consolidated balance sheets. Further, a portion of the earnings and losses of HTALP are allocated to noncontrolling interest holders based on their respective ownership percentages. Upon conversion of OP Units to common stock, any difference between the fair value of the common stock issued and the carrying value of the OP Units converted to common stock is recorded as a component of equity. As of September 30, 2017 and December 31, 2016 , there were approximately 4.1 million and 4.3 million , respectively, of OP Units issued and outstanding. VIEs are entities where investors lack sufficient equity at risk for the entity to finance its activities without additional subordinated financial support or where equity investors, as a group, lack one of the following: (i) the power to direct the activities that most significantly impact the entity’s economic performance; (ii) the obligation to absorb the expected losses of the entity; and (iii) the right to receive the expected returns of the entity. We consolidate our investment in VIEs when we determine that we are the primary beneficiary. A primary beneficiary is one that has both: (i) the power to direct the activities of the VIE that most significantly impacts the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The HTALP operating partnership and our other joint venture arrangements are VIEs because the limited partners in those partnerships, although entitled to vote on certain matters, do not possess kick-out rights or substantive participating rights. Additionally, we determined that we are the primary beneficiary of our VIEs. Accordingly, we consolidate our interests in the HTALP operating partnership and in our other joint venture arrangements. However, because we hold what is deemed a majority voting interest in the HTALP operating partnership and our other joint venture arrangements, it qualifies for the exemption from providing certain disclosure requirements associated with investments in VIEs. We will evaluate on an ongoing basis the need to consolidate entities based on the standards set forth in GAAP as described above. Unconsolidated Joint Ventures We account for our investments in unconsolidated joint ventures using the equity method of accounting because we have the ability to exercise significant influence, but not control, over the financial and operational policy decisions of the investments. Using the equity method of accounting, the initial investment is recognized at cost and subsequently adjusted for our share of the net income or loss and any distributions from the joint venture.
Recently Issued or Adopted Accounting Pronouncements	Recently Issued or Adopted Accounting Pronouncements The following table provides a brief description of recently adopted accounting pronouncements: Accounting Pronouncement Description Effective Date Effect on financial statements ASU 2017-01 Business Combinations: (Issued January 2017) ASU 2017-01 clarifies the definition of a business by adding guidance to assist entities evaluate whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting, including, but not limited to, acquisitions, disposals, goodwill and consolidation. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We adopted ASU 2017-01 as of January 1, 2017 on a prospective basis. We expect that the majority of our future investments in real estate will be accounted for as asset acquisitions under ASU 2017-01. The adoption of ASU 2017-01 will impact how we account for acquisition-related expenses and contingent consideration, which may result in lower acquisition-related expenses and eliminate fair value adjustments related to future contingent consideration arrangements. The following table provides a brief description of recently issued accounting pronouncements: Accounting Pronouncement Description Effective Date Effect on financial statements ASU 2014-09 Revenue from Contracts with Customers (Issued May 2014) ASU 2014-09 is a comprehensive new five-step model requiring a company to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (i.e., payment) to which the company expects to be entitled in exchange for those goods or services. Expanded quantitative and qualitative disclosures regarding revenue recognition will be required for contracts that are subject to ASU 2014-09. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach. In August 2015, the FASB deferred the effective date of ASU 2014-09 to the first interim period within annual reporting periods beginning after December 15, 2017 along with the right of early adoption as of the original effective date. We have identified all of our revenue streams and concluded rental income from leasing arrangements represents a substantial portion of our revenue and is specifically excluded from ASU 2014-09 and will be governed and evaluated with the anticipated adoption of ASU 2016-02 as described below. Upon adoption of ASU 2016-02, ASU 2014-09 may apply to executory costs and other components of revenue due under leases that are deemed to be non-lease components (such as common area maintenance and other reimbursement revenue), even when the revenue for such activities is not separately stipulated in the lease. In that case, the revenue from these items previously recognized on a straight-line basis under the current lease guidance would be recognized under the new revenue guidance as the related services are delivered. As a result, while total revenue recognized over time would not differ under the new guidance, the recognition pattern would be different. Under ASU 2014-09, revenue recognition for real estate sales is largely based on the transfer of control versus continuing involvement under the current guidance. Upon adoption, there will not be a material impact on our consolidated financial statements since we have historically disposed of the majority of our properties with no future controls or contingencies. We will adopt ASU 2014-09 effective January 1, 2018 using the modified retrospective approach. ASU 2016-02 Leases (Issued February 2016) ASU 2016-02 will supersede the existing guidance for lease accounting and states that companies will be required to recognize lease assets and lease liabilities on the balance sheet and disclose key information about leasing arrangements. ASU 2016-02 requires qualitative and quantitative disclosures to supplement the amounts recorded in the financial statements so that users can understand the nature of the entity’s leasing activities, including significant judgments and changes in judgments. Within ASU 2016-02 lessor accounting remained fairly unchanged. In adopting ASU 2016-02, companies will be required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. ASU 2016-02 is effective for the fiscal years beginning after December 15, 2018 with early adoption permitted. We are still evaluating the full impact of ASU 2016-02 on our consolidated financial statements, however, we will adopt ASU 2016-02 as of January 1, 2019 and anticipate that we will elect a practical expedient offered in ASU 2016-02 that allows an entity to not reassess the following upon adoption (elected as a group): (i) whether an expired or existing contract contains a lease arrangement; (ii) lease classification related to expired or existing lease arrangements; or (iii) whether costs incurred on expired or existing leases qualify as initial direct costs. As a result of the adoption, all new or amended leases for which we are the lessee, including corporate and ground leases, that are entered into on or after January 1, 2019, will be recorded on our consolidated financial statements as either financing leases or operating leases with a related right of use asset and lease liability. In addition, we expect that certain executory and non-lease components, such as common area maintenance, will need to be accounted for separately from the lease component of the lease. Lease components will continue to be recognized on a straight-line basis over the lease term and certain non-lease components will be accounted for under the new revenue recognition guidance in ASU 2014-09 as mentioned above. Accounting Pronouncement Description Effective Date Effect on financial statements ASU 2016-13 Financial Instruments Credit Losses: Measurement of Credit Losses on Financial Instruments (Issued June 2016) ASU 2016-13 is intended to improve financial reporting by requiring more timely recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. ASU 2016-13 requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected through an allowance for credit losses that is deducted from the amortized cost basis. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019 with early adoption permitted. We do not anticipate early adoption or there to be a material impact, however, we are evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements. ASU 2016-15 Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments (Issued August 2016) ASU 2016-15 clarifies the guidance on the classification of certain cash receipts and payments in the statement of cash flows to reduce diversity in practice with respect to: (i) debt prepayment or debt extinguishment costs; (ii) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (iii) contingent consideration payments made after a business combination; (iv) proceeds from the settlement of insurance claims; (v) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (vi) distributions received from equity method investees; (vii) beneficial interests in securitization transactions; and (viii) separately identifiable cash flows and application of the predominance principle. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We will adopt ASU 2016-15 during the fourth quarter of 2017 and apply the standard retrospectively for all periods presented. We will reclass cash payments related to debt prepayment and extinguishment costs from operating activities to financing activities. Based on our initial assessment the other listed provisions will not have a material impact on our consolidated financial statements and related notes resulting from the adoption of this standard. ASU 2016-18 Statement of Cash Flows: Restricted Cash (Issued November 2016) ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We will adopt ASU 2016-18 during the fourth quarter of 2017 and apply the standard retrospectively for all periods presented. Restricted cash and escrow deposits consist primarily of cash escrowed for real estate acquisitions, real estate taxes, property insurance and capital improvements. We will provide a reconciliation of the changes in cash and cash equivalents and restricted cash and escrow deposits within our consolidated balance sheets to the consolidated statement of cash flows. ASU 2017-05 Other Income: Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets (Issued February 2017) ASU 2017-05 defines an in-substance nonfinancial asset, unifies guidance related to partial sales of nonfinancial assets, eliminates rules specifically addressing the sales of real estate, removes exception to the financial asset derecognition model and clarifies the accounting for contributions of nonfinancial assets to joint ventures. ASU 2017-05 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We will adopt ASU 2017-05 as of January 1, 2018. We do not anticipate there to be a material impact on our consolidated financial statements, as we currently do not have this type of income. However, going forward we will continue to monitor any future impact. ASU 2017-09 Compensation - Stock Compensation (Topic 718): Clarifying the Scope of Modification (Issued May 2017) ASU 2017-09 amends the scope of modification accounting for share-based payment arrangements and provides guidance on the types of changes to the terms and conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We will adopt ASU 2017-09 as of January 1, 2018. We do not anticipate there to be a material impact on our consolidated financial statements. ASU 2017-12 Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (Issued August 2017) ASU 2017-12 expands and refines hedge accounting for both financial (e.g., interest rate) and non-financial risk components, aligns the recognition and presentation of the effects of hedging instruments and hedge items in the financial statements, and includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. ASU 2017-12 is effective for fiscal years beginning after December 15, 2018 with early adoption permitted. We do not anticipate early adoption, however, we are evaluating the impact of adopting ASU 2017-12 on our consolidated financial statements.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Description of Recently Issued Accounting Pronouncements	The following table provides a brief description of recently adopted accounting pronouncements: Accounting Pronouncement Description Effective Date Effect on financial statements ASU 2017-01 Business Combinations: (Issued January 2017) ASU 2017-01 clarifies the definition of a business by adding guidance to assist entities evaluate whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting, including, but not limited to, acquisitions, disposals, goodwill and consolidation. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We adopted ASU 2017-01 as of January 1, 2017 on a prospective basis. We expect that the majority of our future investments in real estate will be accounted for as asset acquisitions under ASU 2017-01. The adoption of ASU 2017-01 will impact how we account for acquisition-related expenses and contingent consideration, which may result in lower acquisition-related expenses and eliminate fair value adjustments related to future contingent consideration arrangements. The following table provides a brief description of recently issued accounting pronouncements: Accounting Pronouncement Description Effective Date Effect on financial statements ASU 2014-09 Revenue from Contracts with Customers (Issued May 2014) ASU 2014-09 is a comprehensive new five-step model requiring a company to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (i.e., payment) to which the company expects to be entitled in exchange for those goods or services. Expanded quantitative and qualitative disclosures regarding revenue recognition will be required for contracts that are subject to ASU 2014-09. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach. In August 2015, the FASB deferred the effective date of ASU 2014-09 to the first interim period within annual reporting periods beginning after December 15, 2017 along with the right of early adoption as of the original effective date. We have identified all of our revenue streams and concluded rental income from leasing arrangements represents a substantial portion of our revenue and is specifically excluded from ASU 2014-09 and will be governed and evaluated with the anticipated adoption of ASU 2016-02 as described below. Upon adoption of ASU 2016-02, ASU 2014-09 may apply to executory costs and other components of revenue due under leases that are deemed to be non-lease components (such as common area maintenance and other reimbursement revenue), even when the revenue for such activities is not separately stipulated in the lease. In that case, the revenue from these items previously recognized on a straight-line basis under the current lease guidance would be recognized under the new revenue guidance as the related services are delivered. As a result, while total revenue recognized over time would not differ under the new guidance, the recognition pattern would be different. Under ASU 2014-09, revenue recognition for real estate sales is largely based on the transfer of control versus continuing involvement under the current guidance. Upon adoption, there will not be a material impact on our consolidated financial statements since we have historically disposed of the majority of our properties with no future controls or contingencies. We will adopt ASU 2014-09 effective January 1, 2018 using the modified retrospective approach. ASU 2016-02 Leases (Issued February 2016) ASU 2016-02 will supersede the existing guidance for lease accounting and states that companies will be required to recognize lease assets and lease liabilities on the balance sheet and disclose key information about leasing arrangements. ASU 2016-02 requires qualitative and quantitative disclosures to supplement the amounts recorded in the financial statements so that users can understand the nature of the entity’s leasing activities, including significant judgments and changes in judgments. Within ASU 2016-02 lessor accounting remained fairly unchanged. In adopting ASU 2016-02, companies will be required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. ASU 2016-02 is effective for the fiscal years beginning after December 15, 2018 with early adoption permitted. We are still evaluating the full impact of ASU 2016-02 on our consolidated financial statements, however, we will adopt ASU 2016-02 as of January 1, 2019 and anticipate that we will elect a practical expedient offered in ASU 2016-02 that allows an entity to not reassess the following upon adoption (elected as a group): (i) whether an expired or existing contract contains a lease arrangement; (ii) lease classification related to expired or existing lease arrangements; or (iii) whether costs incurred on expired or existing leases qualify as initial direct costs. As a result of the adoption, all new or amended leases for which we are the lessee, including corporate and ground leases, that are entered into on or after January 1, 2019, will be recorded on our consolidated financial statements as either financing leases or operating leases with a related right of use asset and lease liability. In addition, we expect that certain executory and non-lease components, such as common area maintenance, will need to be accounted for separately from the lease component of the lease. Lease components will continue to be recognized on a straight-line basis over the lease term and certain non-lease components will be accounted for under the new revenue recognition guidance in ASU 2014-09 as mentioned above. Accounting Pronouncement Description Effective Date Effect on financial statements ASU 2016-13 Financial Instruments Credit Losses: Measurement of Credit Losses on Financial Instruments (Issued June 2016) ASU 2016-13 is intended to improve financial reporting by requiring more timely recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. ASU 2016-13 requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected through an allowance for credit losses that is deducted from the amortized cost basis. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019 with early adoption permitted. We do not anticipate early adoption or there to be a material impact, however, we are evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements. ASU 2016-15 Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments (Issued August 2016) ASU 2016-15 clarifies the guidance on the classification of certain cash receipts and payments in the statement of cash flows to reduce diversity in practice with respect to: (i) debt prepayment or debt extinguishment costs; (ii) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (iii) contingent consideration payments made after a business combination; (iv) proceeds from the settlement of insurance claims; (v) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (vi) distributions received from equity method investees; (vii) beneficial interests in securitization transactions; and (viii) separately identifiable cash flows and application of the predominance principle. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We will adopt ASU 2016-15 during the fourth quarter of 2017 and apply the standard retrospectively for all periods presented. We will reclass cash payments related to debt prepayment and extinguishment costs from operating activities to financing activities. Based on our initial assessment the other listed provisions will not have a material impact on our consolidated financial statements and related notes resulting from the adoption of this standard. ASU 2016-18 Statement of Cash Flows: Restricted Cash (Issued November 2016) ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We will adopt ASU 2016-18 during the fourth quarter of 2017 and apply the standard retrospectively for all periods presented. Restricted cash and escrow deposits consist primarily of cash escrowed for real estate acquisitions, real estate taxes, property insurance and capital improvements. We will provide a reconciliation of the changes in cash and cash equivalents and restricted cash and escrow deposits within our consolidated balance sheets to the consolidated statement of cash flows. ASU 2017-05 Other Income: Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets (Issued February 2017) ASU 2017-05 defines an in-substance nonfinancial asset, unifies guidance related to partial sales of nonfinancial assets, eliminates rules specifically addressing the sales of real estate, removes exception to the financial asset derecognition model and clarifies the accounting for contributions of nonfinancial assets to joint ventures. ASU 2017-05 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We will adopt ASU 2017-05 as of January 1, 2018. We do not anticipate there to be a material impact on our consolidated financial statements, as we currently do not have this type of income. However, going forward we will continue to monitor any future impact. ASU 2017-09 Compensation - Stock Compensation (Topic 718): Clarifying the Scope of Modification (Issued May 2017) ASU 2017-09 amends the scope of modification accounting for share-based payment arrangements and provides guidance on the types of changes to the terms and conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We will adopt ASU 2017-09 as of January 1, 2018. We do not anticipate there to be a material impact on our consolidated financial statements. ASU 2017-12 Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (Issued August 2017) ASU 2017-12 expands and refines hedge accounting for both financial (e.g., interest rate) and non-financial risk components, aligns the recognition and presentation of the effects of hedging instruments and hedge items in the financial statements, and includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. ASU 2017-12 is effective for fiscal years beginning after December 15, 2018 with early adoption permitted. We do not anticipate early adoption, however, we are evaluating the impact of adopting ASU 2017-12 on our consolidated financial statements.

Investments in Real Estate (Tab

Investments in Real Estate (Tables)	9 Months Ended
	Sep. 30, 2017
Investments [Abstract]
Schedule of Purchase Price Allocation	The allocations for these investments, in which we own a controlling financial interest, are set forth below in the aggregate for the nine months ended September 30, 2017 and 2016 , respectively (in thousands): Nine Months Ended September 30, 2017 2016 Land $ 93,064 $ 77,949 Building and improvements 2,336,544 505,138 In place leases 187,890 50,997 Below market leases (27,817 ) (12,790 ) Above market leases 11,718 4,413 Below market leasehold interests 54,252 4,188 Above market leasehold interests (8,978 ) (50 ) Below market debt — 360 Interest rate swaps — (779 ) Net assets acquired 2,646,673 629,426 Other, net (1) 60,781 3,540 Aggregate purchase price $ 2,707,454 $ 632,966 (1) For the nine months ended September 30, 2017, other, net, consisted primarily of capital expenditures and tenant improvements received as credits at the time of acquisition.
Schedule of Weighted Average Lives of Acquired Intangible Assets and Liabilities	The acquired intangible assets and liabilities referenced above had weighted average lives of the following for the nine months ended September 30, 2017 and 2016 , respectively (in years): Nine Months Ended September 30, 2017 2016 Acquired intangible assets 20.6 9.1 Acquired intangible liabilities 19.9 8.3

Intangible Assets and Liabili26

Intangible Assets and Liabilities (Tables)	9 Months Ended
	Sep. 30, 2017
Identified Intangibles, Net [Abstract]
Schedule of Intangible Assets and Liabilities	Intangible assets and liabilities consisted of the following as of September 30, 2017 and December 31, 2016 , respectively (in thousands, except weighted average remaining amortization): September 30, 2017 December 31, 2016 Balance Weighted Average Remaining Amortization in Years Balance Weighted Average Remaining Amortization in Years Assets: In place leases $ 478,052 9.7 $ 294,597 9.7 Tenant relationships 170,539 10.7 172,974 10.6 Above market leases 39,724 6.3 28,401 6.3 Below market leasehold interests 92,362 63.4 38,136 60.4 780,677 534,108 Accumulated amortization (299,398 ) (256,305 ) Total $ 481,279 19.2 $ 277,803 16.1 Liabilities: Below market leases $ 61,788 14.7 $ 34,370 18.6 Above market leasehold interests 20,610 50.3 11,632 53.0 82,398 46,002 Accumulated amortization (12,546 ) (8,946 ) Total $ 69,852 24.9 $ 37,056 28.5
Summary of Net Intangible Amortization	The following is a summary of the net intangible amortization for the three and nine months ended September 30, 2017 and 2016 , respectively (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Amortization recorded against rental income related to above and (below) market leases $ (108 ) $ (115 ) $ (371 ) $ 202 Rental expense related to above and (below) market leasehold interests 322 118 617 321 Amortization expense related to in place leases and tenant relationships 18,757 15,266 45,944 39,483

Receivables and Other Assets (T

Receivables and Other Assets (Tables)	9 Months Ended
	Sep. 30, 2017
Receivables and Other Assets [Abstract]
Schedule of Receivables and Other Assets	Receivables and other assets consisted of the following as of September 30, 2017 and December 31, 2016 , respectively (in thousands): September 30, 2017 December 31, 2016 Tenant receivables, net $ 14,417 $ 8,722 Other receivables, net 10,161 9,233 Deferred financing costs, net 8,190 4,198 Deferred leasing costs, net 23,794 20,811 Straight-line rent receivables, net 83,133 74,052 Prepaid expenses, deposits, equipment and other, net 65,383 55,904 Derivative financial instruments - interest rate swaps 952 541 Total $ 206,030 $ 173,461
Summary of Amortization of Deferred Leasing Costs and Deferred Financing Costs	The following is a summary of the amortization of deferred leasing costs and financing costs for the three and nine months ended September 30, 2017 and 2016 , respectively (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Amortization expense related to deferred leasing costs $ 1,445 $ 1,224 $ 4,179 $ 3,368 Interest expense related to deferred financing costs 398 331 1,061 994

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Schedule of Debt	Debt consisted of the following as of September 30, 2017 and December 31, 2016 , respectively (in thousands): September 30, 2017 December 31, 2016 Unsecured revolving credit facility $ 75,000 $ 88,000 Unsecured term loans 500,000 500,000 Unsecured senior notes 1,850,000 950,000 Fixed rate mortgages loans 415,853 204,562 Variable rate mortgages loans 38,169 38,904 2,879,022 1,781,466 Deferred financing costs, net (16,552 ) (9,527 ) Discount, net (5,712 ) (3,034 ) Total $ 2,856,758 $ 1,768,905
Summary of Debt Maturities and Scheduled Principal Debt Repayments	The following table summarizes the debt maturities and scheduled principal repayments of our indebtedness as of September 30, 2017 (in thousands): Year Amount Remainder of 2017 $ 1,166 2018 100,827 2019 105,940 2020 144,892 2021 303,933 Thereafter 2,222,264 Total $ 2,879,022
Schedule of Amortization of Deferred Financing Costs	As of September 30, 2017 , the future amortization of our deferred financing costs is as follows (in thousands): Year Amount Remainder of 2017 $ 618 2018 2,821 2019 2,826 2020 2,804 2021 2,610 Thereafter 4,873 Total $ 16,552

Derivative Financial Instrume29

Derivative Financial Instruments and Hedging Activities (Tables)	9 Months Ended
	Sep. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Interest Rate Derivatives	As of September 30, 2017 , we had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk (in thousands, except number of instruments): Interest Rate Swaps September 30, 2017 Number of instruments 5 Notional amount $ 189,751 The table below presents the fair value of our derivative financial instruments designated as a hedge as well as our classification in the accompanying condensed consolidated balance sheets as of September 30, 2017 (in thousands). In March 2017 , we designated our derivative financial instruments as cash flow hedges. As such, prior to March 2017 we did not have derivatives designated as hedging instruments. Asset Derivatives Liability Derivatives Fair Value at: Fair Value at: Derivatives Designated as Hedging Instruments: Balance Sheet Location September 30, 2017 December 31, 2016 Balance Sheet Location September 30, 2017 December 31, 2016 Interest rate swaps Receivables and other assets $ 952 $ — Derivative financial instruments $ 1,441 $ — The tables below present the gain or loss recognized on our derivative financial instruments designated as hedges as well as our classification in the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2017 and 2016 (in thousands). In March 2017 , we designated our derivative financial instruments as cash flow hedges. As such, prior to March 2017 we did not have derivatives designated as hedging instruments. Gain (Loss) Recognized in OCI on Derivative (Effective Portion): Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion): Gain (Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing): Three Months Ended September 30, Three Months Ended September 30, Three Months Ended September 30, Derivatives Cash Flow Hedging Relationships: 2017 2016 Statement of Operations Location 2017 2016 Statement of Operations Location 2017 2016 Interest rate swaps $ 9 $ — Interest related to derivative financial instruments $ (196 ) $ — Interest related to derivative financial instruments $ (4 ) $ — Gain (Loss) Recognized in OCI on Derivative (Effective Portion): Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion): Gain (Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing): Nine Months Ended September 30, Nine Months Ended September 30, Nine Months Ended September 30, Derivatives Cash Flow Hedging Relationships: 2017 2016 Statement of Operations Location 2017 2016 Statement of Operations Location 2017 2016 Interest rate swaps $ (1,196 ) $ — Interest related to derivative financial instruments $ (565 ) — Interest related to derivative financial instruments $ (31 ) $ —
Gross Fair Value of Derivative Financial Instruments	The table below presents the fair value of our derivative financial instruments not designated as hedges as well as our classification in the accompanying condensed consolidated balance sheets as of December 31, 2016 (in thousands). In March 2017 , we designated our derivative financial instruments as cash flow hedges. As such, as of March 2017 we did not have derivatives not designated as hedging instruments. Asset Derivatives Liability Derivatives Fair Value at: Fair Value at: Derivatives NOT Designated as Hedging Instruments: Balance Sheet Location September 30, 2017 December 31, 2016 Balance Sheet Location September 30, 2017 December 31, 2016 Interest rate swaps Receivables and other assets $ — $ 541 Derivative financial instruments $ — $ 1,920
Schedule of Derivative Assets Subject to Master Netting Arrangements	The table below sets forth the net effects of offsetting and net presentation of our derivatives as of September 30, 2017 and December 31, 2016 , respectively (in thousands). The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets or liabilities are presented in the consolidated balance sheets. Offsetting of Derivative Assets Gross Amounts of Recognized Assets Gross Amounts in the Consolidated Balance Sheets Net Amounts of Assets Presented in the Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount September 30, 2017 $ 952 $ — $ 952 $ — $ — $ 952 December 31, 2016 541 — 541 — — 541
Schedule of Derivative Liabilities Subject to Master Netting Arrangements	Offsetting of Derivative Liabilities Gross Amounts of Recognized Liabilities Gross Amounts in the Consolidated Balance Sheets Net Amounts of Liabilities Presented in the Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount September 30, 2017 $ 1,441 $ — $ 1,441 $ — $ — $ 1,441 December 31, 2016 1,920 — 1,920 — — 1,920

Stockholders' Equity and Part30

Stockholders' Equity and Partners' Capital (Tables)	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Schedule of Restricted Common Stock Activity	The following is a summary of our restricted common stock activity as of September 30, 2017 and 2016 , respectively: September 30, 2017 September 30, 2016 Restricted Common Stock Weighted Average Grant Date Fair Value Restricted Common Stock Weighted Average Grant Date Fair Value Beginning balance 640,870 $ 27.36 487,850 $ 23.13 Granted 292,109 29.75 417,110 29.82 Vested (278,821 ) 25.31 (236,749 ) 23.27 Forfeited (58,384 ) 28.86 (24,391 ) 25.93 Ending balance 595,774 $ 29.39 643,820 $ 27.35

Fair Value of Financial Instr31

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The table below presents our assets and liabilities measured at fair value on a recurring basis as of September 30, 2017 , aggregated by the applicable level in the fair value hierarchy (in thousands): Level 1 Level 2 Level 3 Total Assets: Derivative financial instruments $ — $ 952 $ — $ 952 Liabilities: Derivative financial instruments $ — $ 1,441 $ — $ 1,441 The table below presents our assets and liabilities measured at fair value on a recurring basis as of December 31, 2016 , aggregated by the applicable level in the fair value hierarchy (in thousands): Level 1 Level 2 Level 3 Total Assets: Derivative financial instruments $ — $ 541 $ — $ 541 Liabilities: Derivative financial instruments $ — $ 1,920 $ — $ 1,920
Schedule of Fair Value, Assets Measured on Non-Recurring Basis	The table below presents our assets measured at fair value on a non-recurring basis as of September 30, 2017 , aggregated by the applicable level in the fair value hierarchy (in thousands): Level 1 Level 2 Level 3 Total Assets: MOB (1) $ — $ 1,423 $ — $ 1,423 (1) During the nine months ended September 30, 2017, we recognized a $5.1 million impairment charge to one MOB. The estimated fair value as of September 30, 2017 for this MOB was based upon real estate market comparables. The table below presents our assets measured at fair value on a non-recurring basis as of December 31, 2016 , aggregated by the applicable level in the fair value hierarchy (in thousands): Level 1 Level 2 Level 3 Total Assets: MOB (1) $ — $ 8,191 $ — $ 8,191 (1) During the year ended December 31, 2016, we recognized impairment charges of $1.3 million and $1.8 million to the carrying value of two MOBs. The estimated fair value as of December 31, 2016 for these two MOBs was based upon a pending sales agreement and real estate market comparables.

Per Share Data of HTA (Tables)

Per Share Data of HTA (Tables)	9 Months Ended
	Sep. 30, 2017
HTA, Inc.
Earnings Per Share
Schedule of Earnings Per Share, Basic and Diluted	The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per share of HTA for the three and nine months ended September 30, 2017 and 2016 , respectively (in thousands, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Numerator: Net income $ 13,957 $ 6,639 $ 22,105 $ 30,191 Net income attributable to noncontrolling interests (194 ) (212 ) (715 ) (830 ) Net income attributable to common stockholders $ 13,763 $ 6,427 $ 21,390 $ 29,361 Denominator: Weighted average shares outstanding - basic 200,674 138,807 173,189 134,905 Dilutive shares 4,121 4,331 4,221 3,409 Weighted average shares outstanding - diluted 204,795 143,138 177,410 138,314 Earnings per common share - basic Net income attributable to common stockholders $ 0.07 $ 0.05 $ 0.12 $ 0.22 Earnings per common share - diluted Net income attributable to common stockholders $ 0.07 $ 0.04 $ 0.12 $ 0.21

Per Unit Data of HTALP (Tables)

Per Unit Data of HTALP (Tables)	9 Months Ended
	Sep. 30, 2017
Healthcare Trust of America Holdings, LP (HTALP)
Earnings Per Share
Schedule of Earnings Per Unit, Basic and Diluted	The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per unit of HTALP for the three and nine months ended September 30, 2017 and 2016 , respectively (in thousands, except per unit data): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Numerator: Net income $ 13,957 $ 6,639 $ 22,105 $ 30,191 Net income attributable to noncontrolling interests (28 ) (1 ) (80 ) (28 ) Net income attributable to common unitholders $ 13,929 $ 6,638 $ 22,025 $ 30,163 Denominator: Weighted average units outstanding - basic 204,795 143,137 177,410 138,314 Dilutive units — — — — Weighted average units outstanding - diluted 204,795 143,137 177,410 138,314 Earnings per common unit - basic: Net income attributable to common unitholders $ 0.07 $ 0.05 $ 0.12 $ 0.22 Earnings per common unit - diluted: Net income attributable to common unitholders $ 0.07 $ 0.05 $ 0.12 $ 0.22

Supplemental Cash Flow Inform34

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Sep. 30, 2017
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	The following is the supplemental cash flow information for the nine months ended September 30, 2017 and 2016 , respectively (in thousands): Nine Months Ended September 30, 2017 2016 Supplemental Disclosure of Cash Flow Information: Interest paid $ 51,066 $ 39,321 Income taxes paid 997 934 Supplemental Disclosure of Noncash Investing and Financing Activities: Accrued capital expenditures $ 4,185 $ 2,868 Debt and interest rate swaps assumed and entered into in connection with an acquisition 286,000 21,156 Dividend distributions declared, but not paid 62,494 43,530 Issuance of operating partnership units in connection with an acquisition 610 71,754 Note receivable included in the consideration of a disposition — 3,000 Note receivable retired in connection with an acquisition 2,494 — Redeemable noncontrolling interest assumed in connection with an acquisition — 5,449 Redemption of noncontrolling interest 5,694 5,709

Organization and Description 35

Organization and Description of Business (Details) ft² in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2017USD ($)ft²States
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General partnership interest (as a percent)	98.00%
Concentration Risk [Line Items]
Purchased property inception to current date	$ 7,000
Gross leasable area of real estate in portfolio (in square feet) | ft²	24.2
Investment in unconsolidated joint ventures, ownership percentage	50.00%
Percentage of gross leasable area on-campus/aligned	96.00%
Number of states in which the Company operates | States	33
Maximum state gross leasable area	19.00%
Percentage of gross leasable area located in the top 75 Metro statistical areas	92.00%
Duke
Concentration Risk [Line Items]
Asset acquisition, consideration transferred	$ 2,240
Investment in unconsolidated joint ventures, ownership percentage	50.00%
Investment in unconsolidated joint ventures, amount	$ 68.8

Summary of Significant Accoun36

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Partners' Capital Notes [Abstract]
Investment in unconsolidated joint ventures, ownership percentage	50.00%		50.00%
Investment in unconsolidated joint venture	$ 68,303		$ 68,303		$ 0
Income from unconsolidated joint venture	(318)	$ 0	(381)	$ 0
Building and Building Improvements
Partners' Capital Notes [Abstract]
Depreciation expense	$ 49,800	31,100	$ 121,500	86,600
Healthcare Trust of America Holdings, LP (HTALP)
Partners' Capital Notes [Abstract]
Limited partner's capital, units issued (in shares)	4,116,546		4,116,546		4,323,095
Limited partner's capital, units outstanding (in shares)	4,116,546		4,116,546		4,323,095
Investment in unconsolidated joint venture	$ 68,303		$ 68,303		$ 0
Income from unconsolidated joint venture	$ (318)	$ 0	$ (381)	$ 0

Investments in Real Estate - Ac

Investments in Real Estate - Acquisitions (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Oct. 25, 2017	Sep. 30, 2017	Sep. 30, 2016
Asset Acquisition [Line Items]
Aggregate purchase price		$ 2,700,000
Closing costs		$ 17,200
Healthcare Trust of America Holdings, LP (HTALP)
Asset Acquisition [Line Items]
Number of operating partnership units issued in acquisition (in shares)		20,687
Market value of operating partnership units issued in acquisition		$ 610	$ 71,754
Healthcare Trust of America Holdings, LP (HTALP) | Subsequent Event
Asset Acquisition [Line Items]
Number of operating partnership units issued in acquisition (in shares)	16,972
Market value of operating partnership units issued in acquisition	$ 500
Aggregate purchase price	$ 8,300

Investments in Real Estate - Pu

Investments in Real Estate - Purchase Price Allocation (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Sep. 30, 2016
Asset Acquisition
Land	$ 93,064
Building and improvements	2,336,544
In place leases	187,890
Below market leases	(27,817)
Above market leases	11,718
Below market leasehold interests	54,252
Above market leasehold interests	(8,978)
Below market debt	0
Interest rate swaps	0
Net assets acquired	2,646,673
Other, net	60,781
Aggregate purchase price	$ 2,707,454
Business Combination
Land		$ 77,949
Building and improvements		505,138
In place leases		50,997
Below market leases		(12,790)
Above market leases		4,413
Below market leasehold interests		4,188
Above market leasehold interests		(50)
Below market debt		360
Interest rate swaps		(779)
Net assets acquired		629,426
Other, net		3,540
Aggregate purchase price		$ 632,966

Investments in Real Estate - We

Investments in Real Estate - Weighted Average Lives (Details)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Investments [Abstract]
Acquired intangible assets (in years)	20 years 7 months 20 days	9 years 1 month 6 days
Acquired intangible liabilities (in years)	19 years 11 months 8 days	8 years 3 months 18 days

Impairment and Dispositions (De

Impairment and Dispositions (Details) ft² in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)ft²	Sep. 30, 2016USD ($)facility
Disposal Group, Not Discontinued Operation, Disposal Disclosures [Abstract]
Proceeds from sale of real estate			$ 5,000,000	$ 26,500,000
Area of MOB sold (in square feet) | ft²			48
Impairment	$ 0	$ 0	$ 5,093,000	$ 0
Number of senior care facilities disposed | facility				4

Intangible Assets and Liabili41

Intangible Assets and Liabilities - Summary of Intangible Assets and Liabilities (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Assets
Gross	$ 780,677	$ 534,108
Accumulated amortization	(299,398)	(256,305)
Total	$ 481,279	$ 277,803
Weighted Average Remaining Amortization in Years	19 years 2 months 12 days	16 years 1 month 6 days
Liabilities
Gross	$ 82,398	$ 46,002
Accumulated amortization	(12,546)	(8,946)
Total	$ 69,852	$ 37,056
Weighted Average Remaining Amortization in Years	24 years 10 months 24 days	28 years 6 months
Below market leases
Liabilities
Gross	$ 61,788	$ 34,370
Weighted Average Remaining Amortization in Years	14 years 8 months 12 days	18 years 7 months 6 days
Above market leasehold interests
Liabilities
Gross	$ 20,610	$ 11,632
Weighted Average Remaining Amortization in Years	50 years 3 months 18 days	53 years
In place leases
Assets
Gross	$ 478,052	$ 294,597
Weighted Average Remaining Amortization in Years	9 years 8 months 12 days	9 years 8 months 12 days
Tenant relationships
Assets
Gross	$ 170,539	$ 172,974
Weighted Average Remaining Amortization in Years	10 years 8 months 12 days	10 years 7 months 6 days
Above market leases
Assets
Gross	$ 39,724	$ 28,401
Weighted Average Remaining Amortization in Years	6 years 3 months 18 days	6 years 3 months 18 days
Below market leasehold interests
Assets
Gross	$ 92,362	$ 38,136
Weighted Average Remaining Amortization in Years	63 years 4 months 24 days	60 years 4 months 24 days

Intangible Assets and Liabili42

Intangible Assets and Liabilities - Summary of Intangible Amortization (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Amortization recorded against rental income related to above and (below) market leases
Schedule of Finite-Lived Intangible Assets and Liabilities [Line Items]
Amortization of intangible assets and liabilities	$ (108)	$ (115)	$ (371)	$ 202
Rental expense related to above and (below) market leasehold interests
Schedule of Finite-Lived Intangible Assets and Liabilities [Line Items]
Amortization of intangible assets and liabilities	322	118	617	321
Amortization expense related to in place leases and tenant relationships
Schedule of Finite-Lived Intangible Assets and Liabilities [Line Items]
Amortization of intangible assets and liabilities	$ 18,757	$ 15,266	$ 45,944	$ 39,483

Receivables and Other Assets -

Receivables and Other Assets - Schedule of Receivables and Other Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Receivables and Other Assets [Abstract]
Tenant receivables, net	$ 14,417	$ 8,722
Other receivables, net	10,161	9,233
Deferred financing costs, net	8,190	4,198
Deferred leasing costs, net	23,794	20,811
Straight-line rent receivables, net	83,133	74,052
Prepaid expenses, deposits, equipment and other, net	65,383	55,904
Derivative financial instruments - interest rate swaps	952	541
Total	$ 206,030	$ 173,461

Receivables and Other Assets 44

Receivables and Other Assets - Amortization (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Receivables and Other Assets [Abstract]
Amortization expense related to deferred leasing costs	$ 1,445	$ 1,224	$ 4,179	$ 3,368
Interest expense related to deferred financing costs	$ 398	$ 331	$ 1,061	$ 994

Debt - Schedule of Debt (Detail

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Debt Instrument
Total debt, gross	$ 2,879,022	$ 1,781,466
Deferred financing costs, net	(16,552)	(9,527)
Discount, net	(5,712)	(3,034)
Total	2,856,758	1,768,905
Unsecured term loans
Debt Instrument
Total debt, gross	500,000	500,000
Unsecured senior notes
Debt Instrument
Total debt, gross	1,850,000	950,000
Mortgages | Fixed rate mortgages loans
Debt Instrument
Total debt, gross	415,853	204,562
Mortgages | Variable rate mortgages loans
Debt Instrument
Total debt, gross	38,169	38,904
Unsecured revolving credit facility
Debt Instrument
Unsecured revolving credit facility	$ 75,000	$ 88,000

Debt - Textuals (Details)

Debt - Textuals (Details)	1 Months Ended		3 Months Ended		9 Months Ended
	Jun. 30, 2017USD ($)payment	May 31, 2017USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Jul. 27, 2017USD ($)	Dec. 31, 2016USD ($)
Debt Instrument
Outstanding amount			$ 2,879,022,000		$ 2,879,022,000			$ 1,781,466,000
Proceeds from line of credit					515,000,000	$ 513,000,000
Loss on extinguishment of debt, net			774,000	$ 3,000,000	11,192,000	3,022,000
Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Proceeds from line of credit					515,000,000	513,000,000
Loss on extinguishment of debt, net			774,000	$ 3,000,000	11,192,000	$ 3,022,000
Unsecured term loans
Debt Instrument
Outstanding amount			500,000,000		$ 500,000,000			500,000,000
Unsecured term loans | $300.0 Million Unsecured Term Loan
Debt Instrument
Basis spread on variable rate (as a percent)					1.10%
Outstanding amount			$ 300,000,000		$ 300,000,000		$ 300,000,000
Weighted average interest rate with interest rate swap impact (as a percent)			2.40%		2.40%
Unsecured term loans | $200.0 Million Unsecured Term Loan | Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Basis spread on variable rate (as a percent)					1.65%
Weighted average interest rate with interest rate swap impact (as a percent)			2.93%		2.93%
Debt instrument, face amount			$ 200,000,000		$ 200,000,000
Unsecured term loans | LIBOR | Minimum | $300.0 Million Unsecured Term Loan
Debt Instrument
Basis spread on variable rate (as a percent)					0.90%
Unsecured term loans | LIBOR | Minimum | $200.0 Million Unsecured Term Loan | Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Basis spread on variable rate (as a percent)					1.50%
Unsecured term loans | LIBOR | Maximum | $300.0 Million Unsecured Term Loan
Debt Instrument
Basis spread on variable rate (as a percent)					1.75%
Unsecured term loans | LIBOR | Maximum | $200.0 Million Unsecured Term Loan | Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Basis spread on variable rate (as a percent)					2.45%
Unsecured senior notes
Debt Instrument
Outstanding amount			1,850,000,000		$ 1,850,000,000			$ 950,000,000
Unsecured senior notes | $300.0 Million Unsecured Senior Notes due 2021 | Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Outstanding amount			300,000,000		300,000,000
Debt instrument, face amount			$ 300,000,000		$ 300,000,000
Debt instrument, stated interest rate (as a percent)			3.38%		3.38%
Debt instrument, percentage of principal amount received (as a percent)			99.21%		99.21%
Debt instrument, effective interest rate (as a percent)			3.50%		3.50%
Unsecured senior notes | $400.0 Million Unsecured Senior Notes due 2022 | Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Outstanding amount			$ 400,000,000		$ 400,000,000
Debt instrument, face amount	$ 400,000,000
Debt instrument, stated interest rate (as a percent)	2.95%
Debt instrument, percentage of principal amount received (as a percent)	99.94%
Debt instrument, effective interest rate (as a percent)	2.96%
Unsecured senior notes | $500.0 Million Unsecured Senior Notes due 2027 | Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Outstanding amount			500,000,000		500,000,000
Debt instrument, face amount	$ 500,000,000
Debt instrument, stated interest rate (as a percent)	3.75%
Debt instrument, percentage of principal amount received (as a percent)	99.49%
Debt instrument, effective interest rate (as a percent)	3.81%
Unsecured senior notes | $300.0 Million Unsecured Senior Notes due 2023 | Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Outstanding amount			300,000,000		300,000,000
Debt instrument, face amount			$ 300,000,000		$ 300,000,000
Debt instrument, stated interest rate (as a percent)			3.70%		3.70%
Debt instrument, percentage of principal amount received (as a percent)			99.19%		99.19%
Debt instrument, effective interest rate (as a percent)			3.80%		3.80%
Unsecured senior notes | $350.0 Million Unsecured Senior Notes due 2026 | Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Outstanding amount			$ 350,000,000		$ 350,000,000
Debt instrument, face amount			$ 350,000,000		$ 350,000,000
Debt instrument, stated interest rate (as a percent)			3.50%		3.50%
Debt instrument, percentage of principal amount received (as a percent)			99.72%		99.72%
Debt instrument, effective interest rate (as a percent)			3.53%		3.53%
Secured Debt | Seller Financing Debt
Debt Instrument
Debt instrument, face amount	$ 286,000,000
Debt instrument, stated interest rate (as a percent)	4.00%
Debt instrument interest payable, number of payments | payment	3
Mortgages
Debt Instrument
Weighted average interest rate with interest rate swap impact (as a percent)			4.46%		4.46%
Weighted average interest rate (as a percent)			4.31%		4.31%
Mortgages | Minimum
Debt Instrument
Debt instrument, effective interest rate (as a percent)			2.70%		2.70%
Mortgages | Maximum
Debt Instrument
Debt instrument, effective interest rate (as a percent)			6.39%		6.39%
Unsecured revolving credit facility
Debt Instrument
Line of credit facility, borrowing capacity							1,300,000,000
Maximum borrowing capacity, conditional increase							750,000,000
Conditional maximum borrowing capacity							2,050,000,000
Basis spread on variable rate (as a percent)					1.00%
Line of credit facility, commitment fee (as a percent)					0.20%
Unsecured revolving credit facility | Minimum
Debt Instrument
Line of credit facility, commitment fee (as a percent)					0.13%
Unsecured revolving credit facility | Maximum
Debt Instrument
Line of credit facility, commitment fee (as a percent)					0.30%
Unsecured revolving credit facility | LIBOR | Minimum
Debt Instrument
Basis spread on variable rate (as a percent)					0.83%
Unsecured revolving credit facility | LIBOR | Maximum
Debt Instrument
Basis spread on variable rate (as a percent)					1.55%
Unsecured revolving credit facility | Line of Credit
Debt Instrument
Line of credit facility, borrowing capacity							$ 1,000,000,000
Line of Credit | Bridge Loan Facility
Debt Instrument
Line of credit facility, borrowing capacity		$ 2,470,000,000
Line of credit facility, expiration period (in days)		364 days
Proceeds from line of credit	$ 0
Loss on extinguishment of debt, net		$ 10,400,000

Debt - Principal Maturity Sched

Debt - Principal Maturity Schedule (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Remainder of 2017	$ 1,166
2,018	100,827
2,019	105,940
2,020	144,892
2,021	303,933
Thereafter	2,222,264
Total	$ 2,879,022	$ 1,781,466

Debt - Amortization of Deferred

Debt - Amortization of Deferred Financing Costs (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Remainder of 2017	$ 618
2,018	2,821
2,019	2,826
2,020	2,804
2,021	2,610
Thereafter	4,873
Total	$ 16,552	$ 9,527

Derivative Financial Instrume49

Derivative Financial Instruments and Hedging Activities - Table of Derivative Financial Instruments (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2017USD ($)derivative	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)derivative	Sep. 30, 2016USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Cash flow hedge ineffectiveness recorded in earnings	$ 4,000		$ 31,000
Derivative
Cash flow hedge gain (loss) expected to be reclassified during the next 12 months			400,000
Gain (loss) on change in fair value of derivative financial instruments, net	0	$ 1,306,000	884,000	$ (2,144,000)
Fair value interest rate derivatives	1,500,000		1,500,000
Aggregate termination value of derivative obligations had provisions been breached	$ 1,500,000		$ 1,500,000
Cash Flow Hedging | Designated as Hedging Instrument | Interest rate swaps
Derivative
Number of derivatives settled | derivative			2
Notional amount of derivatives settled			$ 250,000,000
Derivative term			10 years
Average annual swap rates	2.26%		2.26%
Payment of derivative settlement costs			$ 700,000
Gain (loss) on settlement of derivatives			$ 25,000
Number of instruments (in derivatives) | derivative	5		5
Notional amount	$ 189,751,000		$ 189,751,000

Derivative Financial Instrume50

Derivative Financial Instruments and Hedging Activities - Derivative Instruments Fair Value Table (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Derivatives, Fair Value
Asset Derivatives	$ 952		$ 952		$ 541
Liability Derivatives	1,441		1,441		1,920
Designated as Hedging Instrument | Cash Flow Hedging | Interest rate swaps
Derivatives, Fair Value
Gain (Loss) Recognized in OCI on Derivative (Effective Portion)	9	$ 0	(1,196)	$ 0
Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	(196)	0	(565)	0
Gain (Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing)	(4)	$ 0	(31)	$ 0
Designated as Hedging Instrument | Cash Flow Hedging | Interest rate swaps | Receivables and other assets
Derivatives, Fair Value
Asset Derivatives	952		952		0
Designated as Hedging Instrument | Cash Flow Hedging | Interest rate swaps | Derivative financial instruments
Derivatives, Fair Value
Liability Derivatives	1,441		1,441		0
Not Designated as Hedging Instrument | Cash Flow Hedging | Interest rate swaps | Receivables and other assets
Derivatives, Fair Value
Asset Derivatives	0		0		541
Not Designated as Hedging Instrument | Cash Flow Hedging | Interest rate swaps | Derivative financial instruments
Derivatives, Fair Value
Liability Derivatives	$ 0		$ 0		$ 1,920

Derivative Financial Instrume51

Derivative Financial Instruments and Hedging Activities - Derivative Offsetting (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Offsetting of Derivative Assets
Asset Derivatives	$ 952	$ 541
Gross Amounts in the Consolidated Balance Sheets	0	0
Net Amounts of Assets Presented in the Consolidated Balance Sheets	952	541
Financial Instruments	0	0
Cash Collateral Received	0	0
Net Amount	952	541
Offsetting of Derivative Liabilities
Liability Derivatives	1,441	1,920
Gross Amounts in the Consolidated Balance Sheets	0	0
Net Amounts of Liabilities Presented in the Consolidated Balance Sheets	1,441	1,920
Financial Instruments	0	0
Cash Collateral Received	0	0
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	$ 1,441	$ 1,920

Stockholders' Equity and Part52

Stockholders' Equity and Partners' Capital - Textuals (Details)	Oct. 24, 2017$ / shares	Oct. 25, 2017USD ($)shares	Sep. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2016USD ($)$ / shares	Sep. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2016USD ($)$ / shares
Common Stock Offerings
Total equity issued, including partners' capital units						$ 1,700,000,000
Proceeds from issuance of common stock						1,624,222,000	$ 418,891,000
Issuance of common stock, net						$ 1,624,222,000	$ 417,163,000
Common Stock Dividends
Dividends declared (in dollars per share) | $ / shares				$ 0.305	$ 0.300	$ 0.905	$ 0.890
Restricted Common Stock
Incentive Plan
Nonvested awards, total compensation cost not yet recognized			$ 9,100,000	$ 9,100,000		$ 9,100,000
Period for recognition (in years)						1 year 9 months 18 days
Restricted Common Stock | General and Administrative Expense
Incentive Plan
Compensation expense				$ 1,700,000	$ 2,100,000	$ 5,500,000	$ 5,100,000
2006 Incentive Plan
Incentive Plan
Number of shares authorized (in shares) | shares			5,000,000	5,000,000		5,000,000
Number of shares available for grant (in shares) | shares			1,689,585	1,689,585		1,689,585
Subsequent Event
Common Stock Dividends
Dividends declared (in dollars per share) | $ / shares	$ 0.305
Duke
Common Stock Offerings
Shares issued, price per share (in dollars per share) | $ / shares			$ 28.50	$ 28.50		$ 28.50
Issuance of common stock, net (in shares) | shares						54,625,000
Proceeds from issuance of common stock						$ 1,600,000,000
Weighted Average
Common Stock Offerings
Shares issued, price per share (in dollars per share) | $ / shares			$ 28.70	$ 28.70		$ 28.70
ATM
Common Stock Offerings
Issuance of common stock, net (in shares) | shares						3,998,000
Proceeds from issuance of common stock						$ 125,700,000
Remaining amount of shares available for issuance			$ 500,000,000	$ 500,000,000		$ 500,000,000
ATM | Scenario, Forecast [Member]
Common Stock Offerings
Issuance of common stock, net		$ 75,000,000
ATM | Subsequent Event
Common Stock Offerings
Issuance of common stock, net		$ 200,000,000
ATM | Maximum
Common Stock Offerings
Maximum amount of common stock authorized			$ 500,000,000
ATM | Weighted Average
Common Stock Offerings
Shares issued, price per share (in dollars per share) | $ / shares			$ 31.45	$ 31.45		$ 31.45
Healthcare Trust of America Holdings, LP (HTALP)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend distribution ratio						1
Common Unit Offerings
Issuance of limited partner units in connection with an acquisition (in units) | shares						20,687
Issuance of limited partner units in connection with an acquisition						$ 610,000	$ 71,754,000
Common Stock Dividends
Dividends declared (in dollars per share) | $ / shares				$ 0.305	$ 0.300	$ 0.905	$ 0.890
Healthcare Trust of America Holdings, LP (HTALP) | Subsequent Event
Common Unit Offerings
Issuance of limited partner units in connection with an acquisition (in units) | shares		16,972
Issuance of limited partner units in connection with an acquisition		$ 500,000

Stockholders' Equity and Part53

Stockholders' Equity and Partners' Capital - Restricted Common Stock Activity (Details) - Restricted Common Stock - $ / shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Restricted Common Stock
Balance as of beginning of period (in shares)	640,870	487,850
Granted (in shares)	292,109	417,110
Vested (in shares)	(278,821)	(236,749)
Forfeited (in shares)	(58,384)	(24,391)
Balance as of end of period (in shares)	595,774	643,820
Weighted Average Grant Date Fair Value
Balance as of beginning of period (in dollars per share)	$ 27.36	$ 23.13
Granted (in dollars per share)	29.75	29.82
Vested (in dollars per share)	25.31	23.27
Forfeited (in dollars per share)	28.86	25.93
Balance as of end of period (in dollars per share)	$ 29.39	$ 27.35

Fair Value of Financial Instr54

Fair Value of Financial Instruments - Assets and Liabilities at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Assets:
Derivative financial instruments, asset	$ 952	$ 541
Liabilities:
Derivative financial instrument, liability	1,441	1,920
Fair Value, Measurements, Recurring
Assets:
Derivative financial instruments, asset	952	541
Liabilities:
Derivative financial instrument, liability	1,441	1,920
Fair Value, Measurements, Recurring | Level 1
Assets:
Derivative financial instruments, asset	0	0
Liabilities:
Derivative financial instrument, liability	0	0
Fair Value, Measurements, Recurring | Level 2
Assets:
Derivative financial instruments, asset	952	541
Liabilities:
Derivative financial instrument, liability	1,441	1,920
Fair Value, Measurements, Recurring | Level 3
Assets:
Derivative financial instruments, asset	0	0
Liabilities:
Derivative financial instrument, liability	$ 0	$ 0

Fair Value of Financial Instr55

Fair Value of Financial Instruments - Assets on Nonrecurring Basis (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis [Line Items]
Assets: MOB	$ 1,423	$ 8,191
Impairment charges on MOB	5,100
Medical Office Buildings, Building A
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis [Line Items]
Impairment charges on MOB		1,300
Medical Office Buildings, Building B
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis [Line Items]
Impairment charges on MOB		1,800
Level 1
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis [Line Items]
Assets: MOB	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis [Line Items]
Assets: MOB	1,423	8,191
Level 3
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis [Line Items]
Assets: MOB	$ 0	$ 0

Fair Value of Financial Instr56

Fair Value of Financial Instruments - Textuals (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Debt, fair value	$ 2,913,300	$ 1,784,000
Debt, carrying value	$ 2,856,758	$ 1,768,905

Per Share Data of HTA (Details)

Per Share Data of HTA (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Numerator:
Net income		$ 13,957	$ 6,639	$ 22,105	$ 30,191
Net income attributable to noncontrolling interests	[1]	(194)	(212)	(715)	(830)
Net (loss) income attributable to common stockholders/unitholders		$ 13,763	$ 6,427	$ 21,390	$ 29,361
Denominator:
Weighted average units outstanding - basic (in shares)		200,674	138,807	173,189	134,905
Weighted average number of shares/units outstanding — diluted (in shares)		204,795	143,138	177,410	138,314
Earnings per common share - basic
Net income attributable to common stockholders/unitholders (in dollars per share)		$ 0.07	$ 0.05	$ 0.12	$ 0.22
Earnings per common share - diluted
Net income attributable to common stockholders/unitholders (in dollars per share)		$ 0.07	$ 0.04	$ 0.12	$ 0.21
HTA, Inc.
Numerator:
Net income		$ 13,957	$ 6,639	$ 22,105	$ 30,191
Net income attributable to noncontrolling interests		(194)	(212)	(715)	(830)
Net (loss) income attributable to common stockholders/unitholders		$ 13,763	$ 6,427	$ 21,390	$ 29,361
Denominator:
Weighted average units outstanding - basic (in shares)		200,674	138,807	173,189	134,905
Dilutive shares (in shares)		4,121	4,331	4,221	3,409
Weighted average number of shares/units outstanding — diluted (in shares)		204,795	143,138	177,410	138,314
Earnings per common share - basic
Net income attributable to common stockholders/unitholders (in dollars per share)		$ 0.07	$ 0.05	$ 0.12	$ 0.22
Earnings per common share - diluted
Net income attributable to common stockholders/unitholders (in dollars per share)		$ 0.07	$ 0.04	$ 0.12	$ 0.21
[1]	Includes amounts attributable to redeemable noncontrolling interests.

Per Unit Data of HTALP (Details

Per Unit Data of HTALP (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Numerator:
Net income		$ 13,957	$ 6,639	$ 22,105	$ 30,191
Net income attributable to noncontrolling interests	[1]	(194)	(212)	(715)	(830)
Net (loss) income attributable to common stockholders/unitholders		$ 13,763	$ 6,427	$ 21,390	$ 29,361
Denominator:
Weighted average units outstanding - basic (in shares)		200,674	138,807	173,189	134,905
Weighted average number of shares/units outstanding — diluted (in shares)		204,795	143,138	177,410	138,314
Earnings per common unit - basic:
Net income attributable to common stockholders/unitholders (in dollars per share)		$ 0.07	$ 0.05	$ 0.12	$ 0.22
Earnings per common unit - diluted:
Net income attributable to common stockholders/unitholders (in dollars per share)		$ 0.07	$ 0.04	$ 0.12	$ 0.21
Healthcare Trust of America Holdings, LP (HTALP)
Numerator:
Net income		$ 13,957	$ 6,639	$ 22,105	$ 30,191
Net income attributable to noncontrolling interests		(28)	(1)	(80)	(28)
Net (loss) income attributable to common stockholders/unitholders		$ 13,929	$ 6,638	$ 22,025	$ 30,163
Denominator:
Weighted average units outstanding - basic (in shares)		204,795	143,137	177,410	138,314
Dilutive units (in shares)		0	0	0	0
Weighted average number of shares/units outstanding — diluted (in shares)		204,795	143,137	177,410	138,314
Earnings per common unit - basic:
Net income attributable to common stockholders/unitholders (in dollars per share)		$ 0.07	$ 0.05	$ 0.12	$ 0.22
Earnings per common unit - diluted:
Net income attributable to common stockholders/unitholders (in dollars per share)		$ 0.07	$ 0.05	$ 0.12	$ 0.22
[1]	Includes amounts attributable to redeemable noncontrolling interests.

Supplemental Cash Flow Inform59

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Supplemental Disclosure of Cash Flow Information:
Interest paid	$ 51,066	$ 39,321
Income taxes paid	997	934
Supplemental Disclosure of Noncash Investing and Financing Activities:
Accrued capital expenditures	4,185	2,868
Debt and interest rate swaps assumed and entered into in connection with an acquisition	286,000	21,156
Dividend distributions declared, but not paid	62,494	43,530
Issuance of operating partnership units in connection with an acquisition	610	71,754
Note receivable included in the consideration of a disposition	0	3,000
Note receivable retired in connection with an acquisition	2,494	0
Redeemable noncontrolling interest assumed in connection with an acquisition	0	5,449
Redemption of noncontrolling interest	$ 5,694	$ 5,709